CA2593432A1 - Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene - Google Patents
Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene Download PDFInfo
- Publication number
- CA2593432A1 CA2593432A1 CA002593432A CA2593432A CA2593432A1 CA 2593432 A1 CA2593432 A1 CA 2593432A1 CA 002593432 A CA002593432 A CA 002593432A CA 2593432 A CA2593432 A CA 2593432A CA 2593432 A1 CA2593432 A1 CA 2593432A1
- Authority
- CA
- Canada
- Prior art keywords
- varenicline
- dosage form
- fast disintegrating
- disintegrating dosage
- fast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002552 dosage form Substances 0.000 title claims abstract description 109
- JQSHBVHOMNKWFT-UHFFFAOYSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2C2CC1CNC2 JQSHBVHOMNKWFT-UHFFFAOYSA-N 0.000 title description 2
- 229960004751 varenicline Drugs 0.000 claims abstract description 130
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 claims abstract description 130
- 238000000034 method Methods 0.000 claims abstract description 60
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 42
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 210000000214 mouth Anatomy 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims abstract description 5
- 206010057852 Nicotine dependence Diseases 0.000 claims abstract description 5
- 208000025569 Tobacco Use disease Diseases 0.000 claims abstract description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 33
- -1 Brij.TM.35 Polymers 0.000 claims description 32
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 29
- 229930195725 Mannitol Natural products 0.000 claims description 29
- 235000010355 mannitol Nutrition 0.000 claims description 29
- 239000000594 mannitol Substances 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 239000011230 binding agent Substances 0.000 claims description 27
- 150000001720 carbohydrates Chemical class 0.000 claims description 24
- 235000014633 carbohydrates Nutrition 0.000 claims description 24
- 235000003599 food sweetener Nutrition 0.000 claims description 22
- 239000003765 sweetening agent Substances 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 20
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 19
- 235000010356 sorbitol Nutrition 0.000 claims description 19
- 239000000600 sorbitol Substances 0.000 claims description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 18
- 239000007884 disintegrant Substances 0.000 claims description 18
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 17
- 229920002472 Starch Polymers 0.000 claims description 14
- 235000019698 starch Nutrition 0.000 claims description 14
- 108010010803 Gelatin Proteins 0.000 claims description 13
- 239000008273 gelatin Substances 0.000 claims description 13
- 229920000159 gelatin Polymers 0.000 claims description 13
- 235000019322 gelatine Nutrition 0.000 claims description 13
- 235000011852 gelatine desserts Nutrition 0.000 claims description 13
- 108010011485 Aspartame Proteins 0.000 claims description 12
- 239000000605 aspartame Substances 0.000 claims description 12
- 235000010357 aspartame Nutrition 0.000 claims description 12
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 12
- 229960003438 aspartame Drugs 0.000 claims description 12
- 239000008107 starch Substances 0.000 claims description 12
- 239000000811 xylitol Substances 0.000 claims description 12
- 239000004373 Pullulan Substances 0.000 claims description 11
- 229920001218 Pullulan Polymers 0.000 claims description 11
- 235000019423 pullulan Nutrition 0.000 claims description 11
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 10
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 10
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 10
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 10
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 235000010447 xylitol Nutrition 0.000 claims description 10
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 10
- 229960002675 xylitol Drugs 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 229920001983 poloxamer Polymers 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 229920001285 xanthan gum Polymers 0.000 claims description 8
- 235000010493 xanthan gum Nutrition 0.000 claims description 8
- 239000000230 xanthan gum Substances 0.000 claims description 8
- 229940082509 xanthan gum Drugs 0.000 claims description 8
- 229920000161 Locust bean gum Polymers 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 235000010418 carrageenan Nutrition 0.000 claims description 7
- 229920001525 carrageenan Polymers 0.000 claims description 7
- 239000000679 carrageenan Substances 0.000 claims description 7
- 229940113118 carrageenan Drugs 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 235000010420 locust bean gum Nutrition 0.000 claims description 7
- 239000000711 locust bean gum Substances 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical class [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 6
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 6
- 206010012335 Dependence Diseases 0.000 claims description 6
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 6
- 235000010445 lecithin Nutrition 0.000 claims description 6
- 239000000787 lecithin Substances 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- 229960001855 mannitol Drugs 0.000 claims description 6
- 229940041616 menthol Drugs 0.000 claims description 6
- 230000009529 traumatic brain injury Effects 0.000 claims description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 5
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 5
- 235000019868 cocoa butter Nutrition 0.000 claims description 5
- 229940110456 cocoa butter Drugs 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 5
- 229940068968 polysorbate 80 Drugs 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 229960002920 sorbitol Drugs 0.000 claims description 5
- BLILOGGUTRWFNI-UHFFFAOYSA-N Monomenthyl succinate Chemical compound CC(C)C1CCC(C)CC1OC(=O)CCC(O)=O BLILOGGUTRWFNI-UHFFFAOYSA-N 0.000 claims description 4
- 244000061176 Nicotiana tabacum Species 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 238000009501 film coating Methods 0.000 claims description 4
- 239000007888 film coating Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 3
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 208000032841 Bulimia Diseases 0.000 claims description 3
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000014094 Dystonic disease Diseases 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 206010020651 Hyperkinesia Diseases 0.000 claims description 3
- 208000000269 Hyperkinesis Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 206010034759 Petit mal epilepsy Diseases 0.000 claims description 3
- 208000002389 Pouchitis Diseases 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 3
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 3
- 208000016620 Tourette disease Diseases 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 201000004810 Vascular dementia Diseases 0.000 claims description 3
- 206010047139 Vasoconstriction Diseases 0.000 claims description 3
- 208000003554 absence epilepsy Diseases 0.000 claims description 3
- 208000005298 acute pain Diseases 0.000 claims description 3
- 230000007000 age related cognitive decline Effects 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 208000022531 anorexia Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 229940125717 barbiturate Drugs 0.000 claims description 3
- 229940049706 benzodiazepine Drugs 0.000 claims description 3
- 150000001557 benzodiazepines Chemical class 0.000 claims description 3
- 229960003920 cocaine Drugs 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 206010061428 decreased appetite Diseases 0.000 claims description 3
- 206010013932 dyslexia Diseases 0.000 claims description 3
- 208000010118 dystonia Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 210000004211 gastric acid Anatomy 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 3
- 229960002715 nicotine Drugs 0.000 claims description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 229940005483 opioid analgesics Drugs 0.000 claims description 3
- 208000019906 panic disease Diseases 0.000 claims description 3
- 208000028591 pheochromocytoma Diseases 0.000 claims description 3
- 239000004302 potassium sorbate Substances 0.000 claims description 3
- 235000010241 potassium sorbate Nutrition 0.000 claims description 3
- 229940069338 potassium sorbate Drugs 0.000 claims description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 208000019116 sleep disease Diseases 0.000 claims description 3
- 235000011076 sorbitan monostearate Nutrition 0.000 claims description 3
- 239000001587 sorbitan monostearate Substances 0.000 claims description 3
- 229940035048 sorbitan monostearate Drugs 0.000 claims description 3
- 230000001148 spastic effect Effects 0.000 claims description 3
- 235000019505 tobacco product Nutrition 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- 230000025033 vasoconstriction Effects 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 239000004203 carnauba wax Substances 0.000 claims description 2
- 235000013869 carnauba wax Nutrition 0.000 claims description 2
- 229940082483 carnauba wax Drugs 0.000 claims description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- 235000012245 magnesium oxide Nutrition 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- 235000019814 powdered cellulose Nutrition 0.000 claims description 2
- 229920003124 powdered cellulose Polymers 0.000 claims description 2
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 235000010216 calcium carbonate Nutrition 0.000 claims 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 1
- 229940078495 calcium phosphate dibasic Drugs 0.000 claims 1
- 239000008119 colloidal silica Substances 0.000 claims 1
- 229960005150 glycerol Drugs 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 12
- 241000208125 Nicotiana Species 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 183
- 239000003826 tablet Substances 0.000 description 88
- 239000010408 film Substances 0.000 description 44
- 229960003977 varenicline tartrate Drugs 0.000 description 44
- TWYFGYXQSYOKLK-CYUSMAIQSA-N varenicline tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 TWYFGYXQSYOKLK-CYUSMAIQSA-N 0.000 description 43
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 38
- 239000000796 flavoring agent Substances 0.000 description 37
- 235000019634 flavors Nutrition 0.000 description 36
- 239000004615 ingredient Substances 0.000 description 35
- 239000003814 drug Substances 0.000 description 31
- 229940079593 drug Drugs 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 238000009472 formulation Methods 0.000 description 29
- 239000000463 material Substances 0.000 description 29
- 239000000243 solution Substances 0.000 description 24
- 239000007787 solid Substances 0.000 description 20
- 241000628997 Flos Species 0.000 description 19
- 235000019359 magnesium stearate Nutrition 0.000 description 19
- 238000002156 mixing Methods 0.000 description 17
- 238000000576 coating method Methods 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 239000011248 coating agent Substances 0.000 description 15
- 238000001035 drying Methods 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 239000003086 colorant Substances 0.000 description 14
- 235000019589 hardness Nutrition 0.000 description 14
- 235000000346 sugar Nutrition 0.000 description 14
- 239000000314 lubricant Substances 0.000 description 13
- 239000010409 thin film Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 229940077731 carbohydrate nutrients Drugs 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 12
- 239000011859 microparticle Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 210000003296 saliva Anatomy 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 235000015165 citric acid Nutrition 0.000 description 11
- 238000005469 granulation Methods 0.000 description 11
- 230000003179 granulation Effects 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 229940032147 starch Drugs 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 229960004106 citric acid Drugs 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 9
- 229960001031 glucose Drugs 0.000 description 9
- 230000000873 masking effect Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000007909 solid dosage form Substances 0.000 description 9
- 239000007921 spray Substances 0.000 description 9
- 238000001694 spray drying Methods 0.000 description 9
- 235000005979 Citrus limon Nutrition 0.000 description 8
- 244000131522 Citrus pyriformis Species 0.000 description 8
- 239000001856 Ethyl cellulose Substances 0.000 description 8
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 8
- 235000020971 citrus fruits Nutrition 0.000 description 8
- 235000019325 ethyl cellulose Nutrition 0.000 description 8
- 229920001249 ethyl cellulose Polymers 0.000 description 8
- 239000012458 free base Substances 0.000 description 8
- 150000008163 sugars Chemical class 0.000 description 8
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 7
- 239000005715 Fructose Substances 0.000 description 7
- 229930091371 Fructose Natural products 0.000 description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 7
- 238000013270 controlled release Methods 0.000 description 7
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 239000004005 microsphere Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000000859 sublimation Methods 0.000 description 7
- 230000008022 sublimation Effects 0.000 description 7
- 229960004793 sucrose Drugs 0.000 description 7
- 241000167854 Bourreria succulenta Species 0.000 description 6
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 240000006909 Tilia x europaea Species 0.000 description 6
- 235000011941 Tilia x europaea Nutrition 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 235000019693 cherries Nutrition 0.000 description 6
- 229960001681 croscarmellose sodium Drugs 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000004571 lime Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 229920005862 polyol Polymers 0.000 description 6
- 150000003077 polyols Chemical class 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 5
- 244000144725 Amygdalus communis Species 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 235000009754 Vitis X bourquina Nutrition 0.000 description 5
- 235000012333 Vitis X labruscana Nutrition 0.000 description 5
- 240000006365 Vitis vinifera Species 0.000 description 5
- 235000014787 Vitis vinifera Nutrition 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 239000001099 ammonium carbonate Substances 0.000 description 5
- 239000008122 artificial sweetener Substances 0.000 description 5
- 235000021311 artificial sweeteners Nutrition 0.000 description 5
- 239000001506 calcium phosphate Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 239000011888 foil Substances 0.000 description 5
- 235000007983 food acid Nutrition 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 235000001727 glucose Nutrition 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229920003109 sodium starch glycolate Polymers 0.000 description 5
- 239000008109 sodium starch glycolate Substances 0.000 description 5
- 229940079832 sodium starch glycolate Drugs 0.000 description 5
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 4
- 235000011437 Amygdalus communis Nutrition 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 4
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 4
- 229920003081 Povidone K 30 Polymers 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000000619 acesulfame-K Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003570 air Substances 0.000 description 4
- 235000020224 almond Nutrition 0.000 description 4
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 4
- 239000002269 analeptic agent Substances 0.000 description 4
- 229940043350 citral Drugs 0.000 description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 4
- 239000002826 coolant Substances 0.000 description 4
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 4
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 4
- 229940038472 dicalcium phosphate Drugs 0.000 description 4
- SSNZFFBDIMUILS-UHFFFAOYSA-N dodec-2-enal Chemical compound CCCCCCCCCC=CC=O SSNZFFBDIMUILS-UHFFFAOYSA-N 0.000 description 4
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 229960002737 fructose Drugs 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000000905 isomalt Substances 0.000 description 4
- 235000010439 isomalt Nutrition 0.000 description 4
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 4
- 235000010449 maltitol Nutrition 0.000 description 4
- 239000000845 maltitol Substances 0.000 description 4
- 229940035436 maltitol Drugs 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 4
- 239000008247 solid mixture Substances 0.000 description 4
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 229920000856 Amylose Polymers 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 206010039424 Salivary hypersecretion Diseases 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 235000009499 Vanilla fragrans Nutrition 0.000 description 3
- 244000263375 Vanilla tahitensis Species 0.000 description 3
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 235000010358 acesulfame potassium Nutrition 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229960004543 anhydrous citric acid Drugs 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 239000007891 compressed tablet Substances 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 229960000913 crospovidone Drugs 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 229960002900 methylcellulose Drugs 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 208000026451 salivation Diseases 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229940033134 talc Drugs 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CBOBADCVMLMQRW-UHFFFAOYSA-N 2,6-dimethyloctanal Chemical compound CCC(C)CCCC(C)C=O CBOBADCVMLMQRW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- 229920001685 Amylomaize Polymers 0.000 description 2
- 244000099147 Ananas comosus Species 0.000 description 2
- 235000007119 Ananas comosus Nutrition 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 235000019499 Citrus oil Nutrition 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- 240000000560 Citrus x paradisi Species 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 241000220225 Malus Species 0.000 description 2
- 235000011430 Malus pumila Nutrition 0.000 description 2
- 235000015103 Malus silvestris Nutrition 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 239000006057 Non-nutritive feed additive Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 description 2
- 244000018633 Prunus armeniaca Species 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 235000014443 Pyrus communis Nutrition 0.000 description 2
- 240000001987 Pyrus communis Species 0.000 description 2
- 240000007651 Rubus glaucus Species 0.000 description 2
- 235000011034 Rubus glaucus Nutrition 0.000 description 2
- 235000009122 Rubus idaeus Nutrition 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- YNKMHABLMGIIFX-UHFFFAOYSA-N benzaldehyde;methane Chemical compound C.O=CC1=CC=CC=C1 YNKMHABLMGIIFX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 229960004424 carbon dioxide Drugs 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 230000006949 cholinergic function Effects 0.000 description 2
- WTEVQBCEXWBHNA-YFHOEESVSA-N citral B Natural products CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 2
- 239000010500 citrus oil Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical class C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 2
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008369 fruit flavor Substances 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 229960004903 invert sugar Drugs 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 239000002655 kraft paper Substances 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000008368 mint flavor Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000008601 oleoresin Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 235000019587 texture Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- HVWGTGTZCBPIOH-UHFFFAOYSA-N 1lambda2-stannole Chemical class [Sn]1C=CC=C1 HVWGTGTZCBPIOH-UHFFFAOYSA-N 0.000 description 1
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 229920005682 EO-PO block copolymer Polymers 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 229920003148 Eudragit® E polymer Polymers 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 239000004348 Glyceryl diacetate Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000014766 Mentha X piperi var citrata Nutrition 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 244000007703 Mentha citrata Species 0.000 description 1
- 235000007421 Mentha citrata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000008660 Mentha x piperita subsp citrata Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 235000002431 Monarda citriodora Nutrition 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 235000003893 Prunus dulcis var amara Nutrition 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 108010055615 Zein Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 238000010669 acid-base reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 239000010617 anise oil Substances 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000010620 bay oil Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 229940119201 cedar leaf oil Drugs 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000035127 classic pyoderma gangrenosum Diseases 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 235000019879 cocoa butter substitute Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940085288 combination potassium chloride Drugs 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 238000005111 flow chemistry technique Methods 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 235000019443 glyceryl diacetate Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000008123 high-intensity sweetener Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 1
- 235000019866 hydrogenated palm kernel oil Nutrition 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940127021 low-dose drug Drugs 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229960004011 methenamine Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000010935 mono and diglycerides of fatty acids Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- GYHFUZHODSMOHU-UHFFFAOYSA-N nonanal Chemical compound CCCCCCCCC=O GYHFUZHODSMOHU-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- ZHALDANPYXAMJF-UHFFFAOYSA-N octadecanoate;tris(2-hydroxyethyl)azanium Chemical compound OCC[NH+](CCO)CCO.CCCCCCCCCCCCCCCCCC([O-])=O ZHALDANPYXAMJF-UHFFFAOYSA-N 0.000 description 1
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000007967 peppermint flavor Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000223 polyglycerol Chemical class 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical class CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229940071440 soy protein isolate Drugs 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000005092 sublimation method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 239000001789 thuja occidentalis l. leaf oil Substances 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229940029614 triethanolamine stearate Drugs 0.000 description 1
- 229940057181 varenicline 1 mg Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A fast disintegrating dosage form of varenicline comprising an effective amount of varenicline or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the dosage form disintegrates in a patient's oral cavity in less than three minutes. Also provided are a method for reducing nicotine addiction, aiding in the cessation of, or lessening of tobacco use in a subject by administering to the subject an effective amount of the fast disintegrating dosage form of varenicline or pharmaceutically acceptable salts thereof; a method of treating a disorder or condition by administering an effective amount of the fast disintegrating dosage form of varenicline; and, various methods of manufacturing or forming an immediate dosage form of varenicline.
Description
FAST-DISINTEGRATING DOSAGE FORMS OF
5,8,14-TRIAZATETRACYCLOl10.3.1.02'".04'91-HEXADECA-2(11) 3 5 7 9-PENTAENE
CROSS REFERENCE TO RELATED APPLICATIONS
The present application is a:continuation-in-part of Serial No. 10/300,608, filed Nov.
20, 2002, which claims the benefit of Serial No. 60/334,652, filed Nov. 30, 2001, which is incorporated herein by reference in its entirety.
1. Field of the Invention The present invention relates to pharmaceutical compositions for medicinal uses thereof.
2. Background Art Varenicline has the structure:
:JNH
( N
Varenicline is also known as 5,8,14-triazatetracyclo[10.3.1.02,11.04'9]-hexadeca-2(11),3,5,7,9-pentaene or 7,8,9,1 0-tetrahydro-6,1 0-methano-6H-pyrazino[2,3-h][3]-benzazepine. Varenicline and pharmaceutically acceptable acid addition salts thereof are referred to in PCT International Patent Publication No. WO 99/35131, published July 15, 1999, the contents of which are incorporated herein by reference.
Varenicline binds to neuronal nicotinic acetylcholine specific receptor sites and are useful in modulating cholinergic function. Accordingly, this compound is useful in the treatment of various conditions or diseases including, but not limited ta, inflammatory bowel disease (including, but not limited to, ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome.
Varenicline is a highly potent compound such that dosage forms are necessarily highly diluted with excipients. The excipients provide dosage forms with adequate stability, while also providing for such desirable features as controlling the drug dissolution (e.g., either fast dissolving or slow dissolving in a controlled-release system as described in U.S. Patent Application Publication No. 2003-0180360 and PCT International Application No.
PCT/1B04/01613, the contents of which are hereby incorporated by reference in their entirety), masking bad taste, and providing appropriate properties for preparation of the dosage form (i.e., compression properties for tablets). Finally, varenicline, as a secondary amine, is subject to electrophilic attack. Thus, common excipients such as reducing carbohydrates,can react with the drug.
Because of the high dilution with excipients, reactivity of varenicline with the excipients themselves or with trace impurities (i.e., degradants) of the excipients can be especially problematic. Thus, in the absence of a suitable method for predicting which excipients will provide a balance between stability and other desirable features for dosage formulation, there remains a need for providing appropriate formulations and methods for production of dosage forms of varenicline wherein the drug remains in a predominantly pure form throughout its storage life.
Accordingly, there is a need for providing suitable dosage forms of varenicline, which can be storage-stable for a sufficient time and the dosage can be provided in a relatively pure form over a commercially viable term.
SUMMARY OF THE INVENTION
The present invention provides a fast disintegrating dosage form of varenicline including an effective amount of varenicline or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, wherein the dosage form disintegrates in a patient's oral cavity in less than three minutes. More preferably, the dosage form disintegrates in a patient's oral cavity in less than two minutes and most preferably the dosage form disintegrates in a patient's oral cavity in less than one minute.
Further, the present invention provides a method for reducing nicotine addiction, aiding in the cessation of, or lessening of tobacco use in a subject by administering to the subject an effective amount of the fast disintegrating dosage form of varenicline or pharmaceutically acceptable salts thereof.
Additionally, the present invention provides a method of treating a disorder or condition by administering an effective amount of the fast disintegrating dosage form of varenicline.
Finally, the present invention provides various methods of manufacturing or forming an immediate dosage form of varenicline.
5,8,14-TRIAZATETRACYCLOl10.3.1.02'".04'91-HEXADECA-2(11) 3 5 7 9-PENTAENE
CROSS REFERENCE TO RELATED APPLICATIONS
The present application is a:continuation-in-part of Serial No. 10/300,608, filed Nov.
20, 2002, which claims the benefit of Serial No. 60/334,652, filed Nov. 30, 2001, which is incorporated herein by reference in its entirety.
1. Field of the Invention The present invention relates to pharmaceutical compositions for medicinal uses thereof.
2. Background Art Varenicline has the structure:
:JNH
( N
Varenicline is also known as 5,8,14-triazatetracyclo[10.3.1.02,11.04'9]-hexadeca-2(11),3,5,7,9-pentaene or 7,8,9,1 0-tetrahydro-6,1 0-methano-6H-pyrazino[2,3-h][3]-benzazepine. Varenicline and pharmaceutically acceptable acid addition salts thereof are referred to in PCT International Patent Publication No. WO 99/35131, published July 15, 1999, the contents of which are incorporated herein by reference.
Varenicline binds to neuronal nicotinic acetylcholine specific receptor sites and are useful in modulating cholinergic function. Accordingly, this compound is useful in the treatment of various conditions or diseases including, but not limited ta, inflammatory bowel disease (including, but not limited to, ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome.
Varenicline is a highly potent compound such that dosage forms are necessarily highly diluted with excipients. The excipients provide dosage forms with adequate stability, while also providing for such desirable features as controlling the drug dissolution (e.g., either fast dissolving or slow dissolving in a controlled-release system as described in U.S. Patent Application Publication No. 2003-0180360 and PCT International Application No.
PCT/1B04/01613, the contents of which are hereby incorporated by reference in their entirety), masking bad taste, and providing appropriate properties for preparation of the dosage form (i.e., compression properties for tablets). Finally, varenicline, as a secondary amine, is subject to electrophilic attack. Thus, common excipients such as reducing carbohydrates,can react with the drug.
Because of the high dilution with excipients, reactivity of varenicline with the excipients themselves or with trace impurities (i.e., degradants) of the excipients can be especially problematic. Thus, in the absence of a suitable method for predicting which excipients will provide a balance between stability and other desirable features for dosage formulation, there remains a need for providing appropriate formulations and methods for production of dosage forms of varenicline wherein the drug remains in a predominantly pure form throughout its storage life.
Accordingly, there is a need for providing suitable dosage forms of varenicline, which can be storage-stable for a sufficient time and the dosage can be provided in a relatively pure form over a commercially viable term.
SUMMARY OF THE INVENTION
The present invention provides a fast disintegrating dosage form of varenicline including an effective amount of varenicline or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, wherein the dosage form disintegrates in a patient's oral cavity in less than three minutes. More preferably, the dosage form disintegrates in a patient's oral cavity in less than two minutes and most preferably the dosage form disintegrates in a patient's oral cavity in less than one minute.
Further, the present invention provides a method for reducing nicotine addiction, aiding in the cessation of, or lessening of tobacco use in a subject by administering to the subject an effective amount of the fast disintegrating dosage form of varenicline or pharmaceutically acceptable salts thereof.
Additionally, the present invention provides a method of treating a disorder or condition by administering an effective amount of the fast disintegrating dosage form of varenicline.
Finally, the present invention provides various methods of manufacturing or forming an immediate dosage form of varenicline.
DETAILED DESCRIPTION OF THE INVENTION
Generally, the present invention relates to novel pharmaceutical dosage forms of varenicline:
(%
NH
N
Varenicline is a drug that binds to neuronal nicotinic acetylcholine specific receptor sites, and- is, useful in modulating cholinergic function. For the present invention, the active ingredient can be used per se or in the form of its pharmaceutically acceptable salt, solvate and/or hydrate.
Although any pharmaceutically acceptable form of varenicline can be used in connectiorr with the present invention, it is preferable ta use a salt form of the drug. A
particularly preferred salt form of the drug is the L-tartrate salt. In the present invention, any solid immediate release dosage form can be used. These include, but are not limited to, immediate release tablets, fast disintegrating dosage forms, chewable dosage forms, and the like. Fast disintegrating dosage forms of the present invention are preferred.
More specifically, the present invention relates to fast disintegrating dosage forms (hereinafter, "FDDF") and methods to prepare them. These FDDFs of varenicline are suitable for administration to a patient and are stable dosage forms with uniform drug distribution and potency.
The FDDFs of varenicline include varenicline or a pharmaceutically acceptable salt thereof. Further, the present invention specifically provides a dosage form that includes either the L-tartrate or citrate salt of 5,8,14-triazatetra-cyclo[10.3.1.02'11.04,9]-hexadeca-2(11),3,5,7,9-pentaene. The FDDF of the present invention can be either in the form of an immediate release, a controlled release or both immediate release followed by controlled dosage form.
Additionally, the FDDF of the present invention can include a film coating.
The present invention also relates to processes for production of these film-coated dosage forms.
In particular, the present invention provides a method for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a subject. The method includes steps of administering to a subject an amount of the FDDF of varenicline that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use. More specifically, the varenicline is either the L-tartrate or citrate salt of 5,8,14-triazatetra-cyclo[10.3.1.02,11.04. 9]-hexadeca-2(11),3,5,7,9-pentaene.
The present invention can be used to treat disorders or conditions including, but not limited to, inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions; dependencies on, or addictions to, nicotine, tobacco products, alcohol, benzodiazepines, barbiturates, opioids or cocaine; headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD), Tourette's Syndrome, and any other similar disorder or condition known to those of skill in the art.
The term "immediate-release form," "IR form," or "immediate-release (IR) FDDF"
as used herein means a dosage form which when taken orally substantially provides the drug in a form available to be absorbed into the systemic, circulation within about one hour or less.
The immediate release FDDF of the invention provides a maximum blood concentration of varenicline (Cmax) that is greater than or equal to 80% of that realized for the immediate release, non-FDDF tablet dosage form of varenicline disclosed in U.S. Patent Application Publication No. 2003/0180360A1. Additionally, the immediate release FDDF of the invention provides a maximum area under the curve (AUC) that is greater than or equal to 80% of that realized for the immediate release, non-FDDF tablet dosage form of varenicline. The immediate release FDDF of the invention can further include a glidant, disintegrant, and/or a lubricant. The term also is referred to as "FDDF."
The term "controlled-release form," "CR form," or "controlled-release (CR) FDDF" as used herein means a dosage form which when taken orally substantially provides 50% of the total dose of the drug in a form available to be absorbed into the systemic circulation within about one hour to 15 hours. The controlled release FDDF of the invention can further include a glidant, disintegrant, colorant, flavor and/or a lubricant.
The term "Fast-Disintegrating Dosage Form" or "FDDF" as used herein means dosage forms that disintegrate or dissolve to an extent that the patient believes the solid dosage form to be completely disintegrated or dissolved. That is, the patient can no longer detect any significant lumps or large particles of the original solid dosage form. The term "substantially reducing carbohydrate-free" as used herein means less than approximately 20 wt% of a reducing carbohydrate (including, but not limited to, lactose).
Preferably, dosage forms prepared in accordance with the present invention contain less than 10 wt% of a reducing carbohydrate, and more preferably, less than 5 wt%.
Generally, the present invention relates to novel pharmaceutical dosage forms of varenicline:
(%
NH
N
Varenicline is a drug that binds to neuronal nicotinic acetylcholine specific receptor sites, and- is, useful in modulating cholinergic function. For the present invention, the active ingredient can be used per se or in the form of its pharmaceutically acceptable salt, solvate and/or hydrate.
Although any pharmaceutically acceptable form of varenicline can be used in connectiorr with the present invention, it is preferable ta use a salt form of the drug. A
particularly preferred salt form of the drug is the L-tartrate salt. In the present invention, any solid immediate release dosage form can be used. These include, but are not limited to, immediate release tablets, fast disintegrating dosage forms, chewable dosage forms, and the like. Fast disintegrating dosage forms of the present invention are preferred.
More specifically, the present invention relates to fast disintegrating dosage forms (hereinafter, "FDDF") and methods to prepare them. These FDDFs of varenicline are suitable for administration to a patient and are stable dosage forms with uniform drug distribution and potency.
The FDDFs of varenicline include varenicline or a pharmaceutically acceptable salt thereof. Further, the present invention specifically provides a dosage form that includes either the L-tartrate or citrate salt of 5,8,14-triazatetra-cyclo[10.3.1.02'11.04,9]-hexadeca-2(11),3,5,7,9-pentaene. The FDDF of the present invention can be either in the form of an immediate release, a controlled release or both immediate release followed by controlled dosage form.
Additionally, the FDDF of the present invention can include a film coating.
The present invention also relates to processes for production of these film-coated dosage forms.
In particular, the present invention provides a method for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a subject. The method includes steps of administering to a subject an amount of the FDDF of varenicline that is effective in reducing nicotine addiction or aiding in the cessation or lessening of tobacco use. More specifically, the varenicline is either the L-tartrate or citrate salt of 5,8,14-triazatetra-cyclo[10.3.1.02,11.04. 9]-hexadeca-2(11),3,5,7,9-pentaene.
The present invention can be used to treat disorders or conditions including, but not limited to, inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions; dependencies on, or addictions to, nicotine, tobacco products, alcohol, benzodiazepines, barbiturates, opioids or cocaine; headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD), Tourette's Syndrome, and any other similar disorder or condition known to those of skill in the art.
The term "immediate-release form," "IR form," or "immediate-release (IR) FDDF"
as used herein means a dosage form which when taken orally substantially provides the drug in a form available to be absorbed into the systemic, circulation within about one hour or less.
The immediate release FDDF of the invention provides a maximum blood concentration of varenicline (Cmax) that is greater than or equal to 80% of that realized for the immediate release, non-FDDF tablet dosage form of varenicline disclosed in U.S. Patent Application Publication No. 2003/0180360A1. Additionally, the immediate release FDDF of the invention provides a maximum area under the curve (AUC) that is greater than or equal to 80% of that realized for the immediate release, non-FDDF tablet dosage form of varenicline. The immediate release FDDF of the invention can further include a glidant, disintegrant, and/or a lubricant. The term also is referred to as "FDDF."
The term "controlled-release form," "CR form," or "controlled-release (CR) FDDF" as used herein means a dosage form which when taken orally substantially provides 50% of the total dose of the drug in a form available to be absorbed into the systemic circulation within about one hour to 15 hours. The controlled release FDDF of the invention can further include a glidant, disintegrant, colorant, flavor and/or a lubricant.
The term "Fast-Disintegrating Dosage Form" or "FDDF" as used herein means dosage forms that disintegrate or dissolve to an extent that the patient believes the solid dosage form to be completely disintegrated or dissolved. That is, the patient can no longer detect any significant lumps or large particles of the original solid dosage form. The term "substantially reducing carbohydrate-free" as used herein means less than approximately 20 wt% of a reducing carbohydrate (including, but not limited to, lactose).
Preferably, dosage forms prepared in accordance with the present invention contain less than 10 wt% of a reducing carbohydrate, and more preferably, less than 5 wt%.
The term "buccal delivery" as used herein means a method for drug absorption through the buccal (i.e., inner cheek) tissue.
The term "sublingual delivery" as used herein means delivery of the active compound of the present invention across any tissue under the tongue.
The term "varenicline," as used herein means the parent drug and all pharmaceutically acceptable salts and prodrugs, thereof. The parent drug of varenicline is set forth in International Patent Publication WO 99/35131, published July 15, 1999, the contents of which are incorporated herein by reference.
The term "mgA" refers to the number of milligrams of active drug based on the free base form of the drug.
The term "pharmaceutically acceptable" means the substance or composition must be compatible chemically, physically, and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
The term "pharmaceutically acceptable salt" means non-toxic acid addition salts derived from inorganic and organic acids. Suitable salt derivatives include, but are not limited to, halides, thiocyanates, sulfates, bisulfates, sulfites, bisulfites, arylsulfonates, alkylsulfates, phosphonates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphonates, alkanoates, cycloalkylalkanoates, arylalkonates, adipates, alginates, aspartates, benzoates, fumarates, glucoheptanoates, glycerophosphates, lactates, maleates, nicotinates, oxalates, paimitates, pectinates, picrates, pivalates, succinates, tartarates, citrates, camphorates, camphorsulfonates, digluconates, trifluoroacetates, and the like.
The term "active ingredient" means a therapeutically active compound, as well as any prodrugs thereof and pharmaceutically acceptable salts, hydrates, and solvates of the compound and the prodrugs.
The term "appropriate period of time" or "suitable period of time" means the period of time necessary to achieve a desired effect or result. For example, a mixture can be blended until a potency distribution is reached that is within an acceptable qualitative range for a given application or use of the blended mixture.
The term "unit dose," "unit dosage," or "unit dosage form" means a physically discrete unit that contains a predetermined quantity of active ingredient calculated to produce a desired therapeutic effect. The unit dose or unit dosage can be in the form of a tablet, capsule, sachet, lozenge, thin consumable film, and the like.
The present invention has numerous embodiments. In any of the embodiments, varenicline or any of its pharmaceutically acceptable salts, solvates and/or hydrates can be used. Procedures for making varenicline are described in U.S. Patent No.
The term "sublingual delivery" as used herein means delivery of the active compound of the present invention across any tissue under the tongue.
The term "varenicline," as used herein means the parent drug and all pharmaceutically acceptable salts and prodrugs, thereof. The parent drug of varenicline is set forth in International Patent Publication WO 99/35131, published July 15, 1999, the contents of which are incorporated herein by reference.
The term "mgA" refers to the number of milligrams of active drug based on the free base form of the drug.
The term "pharmaceutically acceptable" means the substance or composition must be compatible chemically, physically, and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
The term "pharmaceutically acceptable salt" means non-toxic acid addition salts derived from inorganic and organic acids. Suitable salt derivatives include, but are not limited to, halides, thiocyanates, sulfates, bisulfates, sulfites, bisulfites, arylsulfonates, alkylsulfates, phosphonates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphonates, alkanoates, cycloalkylalkanoates, arylalkonates, adipates, alginates, aspartates, benzoates, fumarates, glucoheptanoates, glycerophosphates, lactates, maleates, nicotinates, oxalates, paimitates, pectinates, picrates, pivalates, succinates, tartarates, citrates, camphorates, camphorsulfonates, digluconates, trifluoroacetates, and the like.
The term "active ingredient" means a therapeutically active compound, as well as any prodrugs thereof and pharmaceutically acceptable salts, hydrates, and solvates of the compound and the prodrugs.
The term "appropriate period of time" or "suitable period of time" means the period of time necessary to achieve a desired effect or result. For example, a mixture can be blended until a potency distribution is reached that is within an acceptable qualitative range for a given application or use of the blended mixture.
The term "unit dose," "unit dosage," or "unit dosage form" means a physically discrete unit that contains a predetermined quantity of active ingredient calculated to produce a desired therapeutic effect. The unit dose or unit dosage can be in the form of a tablet, capsule, sachet, lozenge, thin consumable film, and the like.
The present invention has numerous embodiments. In any of the embodiments, varenicline or any of its pharmaceutically acceptable salts, solvates and/or hydrates can be used. Procedures for making varenicline are described in U.S. Patent No.
6,410,550, the contents of which are incorporated herein by reference in their entirety. The resolution of racemic mixtures of varenicline is described in W001/62736, which is incorporated herein by reference in its entirety.
In any of the embodiments, pharmaceutical compositions of varenicline can be desirably administered in doses ranging from about 0.1 mgA up to about 6 mgA
per day (where mgA refers to mg of active drug based on the free base form of the drug), more preferably from about 0.5 to 4 mgA/day, and most preferably from about 1 to 4 mgA per day in single or divided doses. Variations in such dosages, however, necessarily occur depending upon the weight and condition of the subject being treated. Depending on individual responses, dosage levels below the lower limit of the aforesaid range can be more than adequate, while in other cases still larger doses can be employed without causing any harmful side effects. The final pharmaceutical composition is processed into a unit dosage form (e.g., tablet, or lozenge or thin film) and then packaged for distribution. The processing step varies depending upon the particular unit dosage form. For example, a tablet is generally compressed under pressure into a desired shape. Those of skill in the art are well aware of the procedures used for manufacturing the various unit dosage forms.
In any embodiments of the present invention, the active blend of an immediate release fast disintegrating dosage form generally includes one or more pharmaceutically acceptable excipients, carriers, or diluents. The particular carrier, diluent, or excipient used-depends upon the means and purpose for which the active ingredient is being applied. In general, an immediate release fast disintegrating dosage form tablet formulation is made of materials including, but not limited to, excipients, diluents, binders, lubricants, glidants, disintegrants, surfactants, colorants, flavors, sweeteners and mixtures thereof. Acceptable excipients include, but are not limited to, starch, mannitol, sorbitol, xylitol, kaolin, calcium sulfate, inorganic salts (e.g., sodium chloride, sodium bicarbonate}, acids such as citric acid, powdered cellulose derivatives, microcrystalline cellulose, silicified microcrystalline cellulose, fast dissolving carbohydrates such as PharmaburstT"', tribasic calcium phosphate, ammonium bicarbonate, calcium sulfate, magnesium carbonate, magnesium oxide, poloxamers which are closely related block copolymers of ethylene oxide and propylene oxide, hydroxypropyl methylcellulose, pullulan, gelatin, carrageenan, gums, combinations thereof, and other similar excipients known to those of skill in the art.
To ensure content uniformity of the blend, a volume mean diameter drug substance particle size of less than or equal to about 60 microns is utilized, more preferably less than or equal to about 40 microns and most preferable less than or equal to about 30 microns.
Preferred diluents are mannitol, sorbitol, xylitol, microcrystalline cellulose (e.g., Avicel(D PH200, PH102 or PH101 available from FMC BioPolymer, Philadelphia, PA), silicified microcrystalline cellulose (such as Prosolv available from PenWest Pharmaceuticals Co., Patterson, NY), cellulosic polymers such as hydroxypropyl methylcellulose (HPMC) and hydroxypropyl cellulose (HPC), pullulan and fast dissolving carbohydrates (such as PharmaburstTA available from SPI Pharma, New Castle, DE). Finally, examples of glidants include, but are not limited to, silicon dioxide, colloidal silicon dioxide, calcium silicate, magnesium silicate, magnesium trisilicate, talc, starch, combinations thereof, and any, other similar glidants known to those of skill in the art.
In any of the embodiments, a binder can be added. Suitable binders include, but are not limited to, substances such as celluloses (e.g., cellulose, methylcellulose, ethylcellulose, hydroxypropyl cellulose and hydroxypropyl methylcellulose), polypropylpyrrolidone, polyvinylprrolidone, gelatin, polyethylene glycol, starch, sugars, trehalose, glucose, sorbitol, natural and synthetic gums (e.g., acacia, alginates, carrageenan, xanthan gum, locust bean gum and gum arabic), waxes, combinations thereof, and any other binder substances known to those of skill in the art.
Further, in any of the embodiments, a lubricant can be used in a tablet formulation to prevent the tablet and punches from sticking in the die. Suitable lubricants include, but are not limited to calcium stearate, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, poloxamer, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, zinc stearate, combinations thereof, and any other suitable lubricants known to those of skill in the art. A preferred lubricant is magnesium stearate. The magnesium stearate is generally present in an amount from about 0.25 wt% to about 4.0 wt%.
Additionally, in any of the embodiments, disintegrants can also be added to the composition to break up the dosage form and release the compound. Suitable disintegrants include, but are not limited to, sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, alginic acid, chitosan, methyl cellulose, microcry,stalline cellulose, powdered cellulose, lower alkyl-substituted hydroxypropyl cellulose, polacrilin potassium, starch, pregelatinized starch, sodium alginate, combinations thereof, and any, other similar disintegrants known to those of skill in the art. Of these, crospovidone, croscarmellose sodium and sodium starch glycolate are preferred, with croscarmellose sodium being most preferred. The croscarmellose sodium is generally present in an amount from about 0.5 wt% to about 6.0 wt%.
Generally, the disintegrant comprises from 1wt% to 15wt%, preferably from 1 wt% to 10 wt% of the dosage form.
In any of the embodiments, a flavor or sweetener can be added. Flavors can be chosen from natural and synthetic flavors. Flavors useful in the present invention include, but are not limited to, volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins or extracts derived from plants, leaves, flowers, fruits, stems, combinations thereof, and other similar flavors known to those of skill in the art. These may include cinnamon oil, oil of wintergreen, peppermint oils, clove oil, bay oil, anise oil, eucalyptus, thyme oil, cedar leaf oil, oil of nutmeg, oil of sage, oil of bitter almonds, and cassia oil. Further oils include, but are not limited to, citrus oils such as lemon, orange, grape, lime and grapefruit and fruit essences including apple, pear, peach, grape, strawberry, raspberry, cherry, plum, pineapple, apricot, and other fruit flavors. Other useful flavorings include, but are not limited to, vanilla, aldehydes and esters such as benzaidehyde (cherry, almond), citral, i.e., alphacitral (lemon, lime), neral, i.e., betal-citral (lemon, lime), decanal (orange, lemon), aldehyde C-8 (citrus fruits), aidehyde C-9 (citrus fruits), aldehyde C-12 (citrus fruits), tolyl aldehyde (cherry, almond), 2,6-dimethyloctanal (green fruit), and 2-dodecenal (citrus, mandarin), combinations thereof, and other similar flavorings known to those of skill in the art.
Sweeteners that can be used with any embodiment of the present invention include, but are not limited to, corn syrup, dextrose, invert sugar, fructose, and mixtures thereof;
saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; sugar alcohols such as sorbitol, mannitol, zylitol;
and the like. Also contemplated are hydrogenated- starch hydrolysates and synthetic sweetener 3,6-dihydro-6-methyi-1-1-1,2,3- oxathiazin-4-one-2,2-dioxide, particularly the potassium salt (acesulfame-K) and sodium and calcium salts thereof, and any other sweeteners known to those of skill in the art.
Other ingredients such as colorants and titanium dioxide can also be included.
In one embodiment of the present invention, the present invention provides a fast disintegrating dosage form of varenicline comprising an effective amount of varenicline or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. The dosage form disintegrates in a patient's oral cavity in less than three minutes.
The fast-disintegrating dosage form of varenicline is a solid dosage form that does not require water to aid swallowing. Oral fast-disintegrating products have the potential of improving the overall clinical performance of a drug by reducing the incidence of non-compliance. A patient who is busy or traveling is more likely to take an oral fast-disintegrating dosage form, than a standard tablet requiring water. The phrase "completely disintegrate, dissolve or disperse"
used in the context of the present invention, means the FDDF dissolves or disintegrates to an extent that the patient believes the solid dosage form to be completely dissolved or disintegrated. That is, the patient can no longer detect any significant lumps or large particles of the original solid dosage form. Instead, at the point in time when the solid dosage from has completely dissolved or disintegrated in the oral cavity of the patient.
These fast disintegrating dosage forms are typically tablets and thin films that dissolve or disperse rapidly when in contact with saliva. In accordance with the present invention, fast disintegrating dosage forms of varenicline dissolve or disintegrate in the oral cavity following administratiori in a time range from about two seconds to about three minutes.
More preferably, disintegration occurs from about two seconds to two minutes, and most preferably from about two seconds to about one minute. The saliva containing the dissolved or dispersed active ingredient is then swallowed.
The preferred formulations of the present invention contain less than about 20% wt reducing carbohydrates. The presence of reducing carbohydrates is detrimental to the drug stability on storage. Reducing carbohydrates are sugars and their derivatives that contain a free aldehyde or ketone group capable of reaction with the secondary amine of varenicline.
Examples of reducing carbohydrates include, but are not limited to, monosaccharides, disaccharides, lactose, glucose, fructose, maltose, and other similar sugars known to those of skill in the art. Further, formulations containing dicalcium phosphate are particularly stable.
More specifically, stable formulations are produced with more than about 20 wt% dicalcium phosphate.
The compositions of the present invention can be prepared utilizing numerous technologies including, but not limited to, spray drying, freeze-drying, heat molding and disintegrant-based and/or sugar-based excipient addition, sublimation, and consumable thin film manufacture.
Spray-drying is a widely used process in the pharmaceutical industry and- can be used to produce highly porous compositions of varenicline. Spray-dried varenicline, as its free base or its suitable salt derivatives, is combined with excipients including, but not iimited to bulking agents such as mannitol, disintegrants such as sodium starch glycolate and croscarmellose sodium, acidic ingredients such as citric acid, glidants and lubricants. This mixture can be blended, granulated, and compressed into tablets as described herein.
Examples of such methods for other drugs are set forth in U.S. Patent Nos.
5,587,180, 5,595,761, 5,635,210, and 5,807,576, each of which is hereby incorporated by reference in its entirety.
The process for spray drying varenicline includes the steps of: (a) dissolving varenicline in a spray solution including a suitable solvent and (b) rapidly evaporating the solvent. Suitable solvents are those that varenicline is soluble including, but not limited to, hydroxylic solvents, non-hydroxylic solvents, water, acetone, tetrahydrofuran, methanol, ethanol, isomeric propanols, combinations thereof, and any other suitable solvents known to those of skill in the art. Alternatively, as varenicline is a low dose drug it could be spray dried with one or more non-volatile excipients as a carrier.
Varenicline should have a solubility of at least 1 wt%, and more preferably at least 5 wt% in the selected solvent. Preferably, the solvent is also volatile with a boiling point of 150 C or less. In addition, the solvent should have relatively low toxicity and be removed from the varenicline to a level that is acceptable according to the International Committee on Harmonization (ICH) guidelines. Removal of solvent to this level can require a subsequent processing step such as tray-drying or fluid bed drying.
In a preferred method, varenicline is spray dried with one or more excipients as a carrier. The rapid evaporation of spray drying achieves yet another advantage, which is the formation of particles having relatively uniform particle size distribution and shape. The particles formed by rapid evaporation have better flow characteristics and are iess likely to become segregated during manufacturing, such as during handling to form tablets. This is particularly important for a drug such as varenicline, since the drug itself has a high potency and therefore is used at a low dose. Reducing segregation during manufacture of the dosage form is important to ensure uniformity of dose in the dosage form. Thus, spray-drying reduces segregation during manufacturing of the dosage form by providing varenicline in a form that is easier to handle. Once the varenicline-containg spray, dried composition has been formed, several processing operations can be used to facilitate incorporation of the varenicline into a dosage form. These processing operations include drying, granulation, milling, compression, and the like.
In another embodiment of the present invention, effervescent excipients are incorporated into a varenicline solid dosage form. Once the dosage form is placed in the patient's oral cavity, contact with saliva promotes the acid-base reaction leading to rapid disintegration and release of the active varenicline. The effervescent sensation is not only pleasant to the patient, but also tends to stimulate saliva production, thereby providing additional water to aid in further effervescence and disintegration. Thus, once the dosage form (usually a tablet) is placed in the patient's mouth, it can disintegrate rapidly and completely without any voluntary action by the patient. Even if the patient does not chew the tablet, disintegration proceeds rapidly. Upon disintegration of the tablet, the active varenicline is released and can be swallowed as a slurry or suspension or it can dissolve in the saliva prior to swallowing. The varenicline can be in the form of a powder or it can be in microparticulate form with one or more excipients. The drug in microparticulate form is the preferred form as optionally it aids in taste-masking.
It is also preferred that the microparticles do not release the active varenicline in the oral cavity. Thus the varenicline can be transferred to the patient's stomach for dissolution in the digestive tract and systemic distribution of the pharmaceutical ingredient. In this way, the dosage form provides taste-masking.
The combination of the effervescent disintegration agent and the microparticles containing the varenicline provides an effective dosage form for systemic distribution. The microparticies can be relatively fragile microparticies susceptible to release of the pharmaceutical ingredient upon rupture of the microparticle. The tablet can disintegrate with minimal or no chewing, thus minimizing the problem of microparticle rupture.
The effervescent disintegration agent includes any compound that evolves gas. The preferred effervescent agents evolve gas by chemical reactions that take place upon exposure of the effervescent disintegration agent to water and/or to saliva in the mouth. The bubble or gas generating reaction is most often the result of the reaction of a soluble acid source such as citric acid and an alkali metal carbonate or carbonate source such as sodium bicarbonate and sodium carbonate. The reaction of these two general classes of compounds produces carbon dioxide gas upon contact with water included in saliva. The dosage form according to this aspect of the present invention can further include one or more additional excipients including flavors, diluents, colors, binders, fillers, and non-effervescent disintegrants and can be chosen from those herein described.
When varenicline is present in microparticles, the microparticle can be provided as a microcapsule or as a matrix-type microparticle. Microcapsules typically incorporate a discrete mass of the pharmaceutical ingredient surrounded by a discrete, separately observable coating of the protective material. Conversely, in a matrix-type particle, the pharmaceutical ingredient is dissolved or suspended throughout the protective material.
Certain microparticles can include attributes of both microcapsules and matrix-type particles. For example, a microparticle can incorporate a core by incorporating the pharmaceutical ingredient in first a protective material and then in a coating of a second protective material, which may be the same as or different from the first protective material surrounding the core.
Alternatively, a microparticle can incorporate a core including the pharmaceutical ingredient and a coating incorporating the protective material, wherein the coating.
itself has some of the pharmaceutical ingredient dispersed within it. These and other known microparticle configurations can be employed.
The microparticles desirably are between about 50 and 800 microns mean outside diameter, and more preferably between about 100 and about 250 microns. Other examples of methodsare set forth in U.S. Patent Nos. 6,210,711, 5,607,697, 5,178,878, 5,503,846, 4,414,198, 5,298,261, 5,188,825, 5,215,756, 5,298,261, 4,687,662, and 4,946,684, the contents of which are hereby incorporated herein by reference in their entirety.
In another embodiment of the present invention, there is provided a method of freeze-drying. Freeze-drying is a common method for preparing porous structures that dissolve rapidly. One embodiment is a freeze-dried tablet that can be produced by admixing a solvent, granular therapeutic agent, and a carrier material such as gelatin. A natural gum such as xanthan gum is then added to the liquid admixture because it behaves synergistically with gelatin as a flocculating agent to improve the ability of the liquid composition to suspend relatively large particles during the manufacturing process. The liquid composition is then placed into one or more shaped depressions in a tray or mold, and then freeze-dried.
Examples of such methods are set forth in U.S. Patent Nos. 6,680,071, 5,738,875, 6,509,040, 5,631,023, 5,843,347, 5,188,825, 4,946,684, 4,642,903, 4,371,516, 4,305,502 and 5,843,347 and PCT International Patent Publications WO 95/01782A2 and WO
00144351A1, the contents of which are hereby incorporated herein by reference in their entirety.
In yet another embodiment of the present invention, there is provided a heat molding method. Fast disintegrating dosage forms of varenicline can be prepared by a method that employs a heat-molding process that involves the steps of setting a molten composition of varenicline. One embodiment consists of an agar solution of a non-reducing sugar such as mannitol as a binder. Examples of such methods are set forth in U.S. Patent Nos. 6,375,982, 6,406,717, 5,466,464, and 5,853,758, the contents of which are hereby incorporated herein by reference in their entirety.
A preferred method of preparing a rapid-melt, semi-solid molded composition of varenicline or its suitable salt derivative includes the following steps:
a) melting at least one binder such as lipid materials, polyethylene glycols (PEG}, waxes and other fats such as cocoa butter in an amount from about 0.01 % to about 70% by weight with a salivating agent such as xylitol, sorbitan monostearate, or polyoxyethylene sorbitan ester in an amount from about 0.05% to about 15% by weight, to form a mixture;
b) mixing a therapeutically effective amount of varenicline with the mixture to form an active mixture;
c) mixing additional excipients such as silicon dioxide, starches, sorbitol, fructose, magnesium stearate, dicalcium phosphate, xylitol, mannitol, maltitol, isomalt, celluloses and mixtures with the active mixture to form a final mixture; and d) molding the final mixture into the rapid-melt, semi-solid molded composition.
The rapid-melt, semi-solid molded compositions can contain at least one binder, a salivating agent, an active material, and a diluent/bulking material.
The combination of excipients allows for fast disintegration of the composition when placed in the mouth of a patient. By pressing the composition on or under the tongue, or between the tongue and cheek of the user, the saliva of the user provides hydration to the composition and allows the composition to disintegrate with little or no chewing. The composition becomes a liquid upon the application of pressure. The semi-solid compositions rapidly disintegrate upon the application of pressure by the tongue of the patient, thus forming a liquid carrier for the active ingredients contained therein. The liquid helps provide the unique characteristics and features of the present inventive compositions.
The rapid-disintegrating, semi-solid compositions of the present invention can include at least one binder. As used herein, "binder" means at least one ingredient useful in keeping the composition in its semi-solid state, and can include, without limitation, a high melting point fat or waxy material such as lipid materials, polyethylene glycols (PEG), waxes, and other fats. Preferably, the semi-solid compositions of the present inventive subject matter include a mixture of binders. The binders useful in the compositions of the present inventive subject matter have a melting point of about 25 to 90 C., and preferably about 37 C.
When more than one binder is used in the compositions of the present invention, the melting point of the combination of the binders remain within the range of 25 to 90 C, and preferably, about 37 C.
The present invention uses mixtures of binders. Among the lipid materials useful as binders in the compositions of the present inventive subject matter are those that are commercially available and commonly used in confectionery and other food products. Such lipid materials include, without limitation, cocoa butter, hydrogenated tallow, hydrogenated vegetable oils, hydrogenated cotton seed oil, palm kernel oil, soybean oil, olive oil, stannol esters, and derivatives and mixtures thereof. Hydrogenated vegetable oils (such as hydrogenated palm kernel oil), cocoa butter, and cocoa butter substitutes are among the preferred useful lipid materials.
The amount of binder present in the rapid-disintegrating, semi-solid molded composition of the present invention is from about 0.01% to about 70% by weight of the final composition. Preferably, the amount of binder is from about a.01 % to about 50% by weight of the composition. More preferably the binder is present from about 15% to about 30% by weight of the composition. The rapid-disintegrating, semi-solid molded composition of the present invention can also contain a salivating agent. As is used herein, "salivating agent"
means a material that promotes greater salivation in the user of the compositions of the present inventive subject matter. The salivating agent helps create salivation in the mouth of the patient using the compositions of the present invention. This is an important feature since the compositions of the present invention are intended to be taken by the patient without the aid of water to help in the transporting of the composition to the stomach of the patient. The salivating agent can be, without limitation, an emulsifier or a food acid that initiates salivation in the mouth of the patient. Examples of emulsifiers useful as salivating agents in the compositions of the present invention include, but are not limited to, alkyl aryl sulfonates, alkyl sulfates, sulfonated amides and amines, sulfated and sulfonated esters and ethers, alkyl sulfonates, polyethoxlyated esters, mono- and diglycerides, diacetyl tartaric esters of monoglycerides, polyglycerol esters, sorbitan esters and ethoxylates, lactylated esters, phospholipids such as lecithin, polyoxyethylene sorbitan esters, proplyene glycol esters, sucrose esters, combinations thereof, and other similar emulsifiers known to those of skill in the art. The emulsifier can be either saturated or unsaturated. Examples of food- acids useful as salivating agents in the inventive compositions include, without limitation, citric acid, malic acid, food salts such as sodium chloride and salt substitutes, potassium chloride, combinations thereof, and other similar food acids known to those of skill in the art.
The amount of salivating agent present in the rapid-melt, semi-solid molded composition of the present invention is from about 0.05% to about 30% by weight of the final composition. Preferably, the amount of salivating agent is from about 0.3% to 20% by weight of the composition. Keeping the amount of salivating, agent present in the inventive composition within these limits for weight percentage is important to enhance the desirable properties of the compositions. More particularly, the low amount of salivating agent present in the compositions aids in the compositions retaining the semi-solid state and the rapidity of melting in the mouth of a patient.
The rapid-disintegrating, semi-solid molded compositions of the present invention can further contain additional excipients to aid in the moisturizing of the composition when chewed. That is, the additional excipients aids in the processability of the compositions. The additional excipients can also serve to reduce the concentration of the active materials and add bulk to the composition. Examples of additional excipients useful in the compositions of the present invention include, but are not limited to, silicon dioxide, sugars, starches, sucrose, sorbitol, fructose, talc, stearic acid, magnesium stearate, dicalcium phosphate, erythitol, xylitol, mannitol, maltitol, isomalt, dextrose, maltose, microcrystalline celluloses, combinations thereof, and other similar additional excipients known to those of skill in the art.
The amount additional excipients present in the semi-solid molded compositions is from about 10% to about 90% by weight of the final composition. Preferably, the amount of additional excipients is from about 35% to about 55% by weight of the final composition.
The use of flavors and sweeteners to mask the taste of the active materials can be used with the compositions of the present invention. Thus, other materials, which can be incorporated into the rapid-melt, semi-solid molded composition of the present inventive subject matter include flavors, colors and sweeteners. A distinct feature of the rapid-melt, semi-solid compositions is that they exhibit excellent taste characteristics.
Importantly, it is possible to incorporate high levels of flavors; sweeteners and other taste-masking agents if desired. Flavors can be chosen from natural and synthetic flavors. Flavors useful in the present invention include, but are not limited to, volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins or extracts derived from plants, leaves, flowers, fruits, stems, combinations thereof, and other similar flavors known to those of skill in the art.
Further oils include, but are not limited to, citrus oils such as lemon, orange, grape, lime and grapefruit and fruit essences including apple, pear, peach, grape, strawberry, raspberry, cherry, plum, pineapple, apricot, and other fruit flavors. Other useful flavorings include, but are not limited to, mint, peppermint, cinnamon, wintergreen, vanilla, aldehydes and esters such as benzaldehyde (cherry, almond), citral, i.e., alphacitral (lemon, lime), neral, i.e., betal-citral (lemon, lime), decanal (orange, lemon}, aidehyde C-8 (citrus fruits), aldehyde C-9 (citrus fruits), aldehyde C-12 (citrus fruits), tolyl aldehyde (cherry, almond), 2,6-dimethyloctanal (green fruit), and 2-dodecenal (citrus, mandarin), combinations thereof, and other similar flavorings known to those of skill in the art.
In any of the embodiments, pharmaceutical compositions of varenicline can be desirably administered in doses ranging from about 0.1 mgA up to about 6 mgA
per day (where mgA refers to mg of active drug based on the free base form of the drug), more preferably from about 0.5 to 4 mgA/day, and most preferably from about 1 to 4 mgA per day in single or divided doses. Variations in such dosages, however, necessarily occur depending upon the weight and condition of the subject being treated. Depending on individual responses, dosage levels below the lower limit of the aforesaid range can be more than adequate, while in other cases still larger doses can be employed without causing any harmful side effects. The final pharmaceutical composition is processed into a unit dosage form (e.g., tablet, or lozenge or thin film) and then packaged for distribution. The processing step varies depending upon the particular unit dosage form. For example, a tablet is generally compressed under pressure into a desired shape. Those of skill in the art are well aware of the procedures used for manufacturing the various unit dosage forms.
In any embodiments of the present invention, the active blend of an immediate release fast disintegrating dosage form generally includes one or more pharmaceutically acceptable excipients, carriers, or diluents. The particular carrier, diluent, or excipient used-depends upon the means and purpose for which the active ingredient is being applied. In general, an immediate release fast disintegrating dosage form tablet formulation is made of materials including, but not limited to, excipients, diluents, binders, lubricants, glidants, disintegrants, surfactants, colorants, flavors, sweeteners and mixtures thereof. Acceptable excipients include, but are not limited to, starch, mannitol, sorbitol, xylitol, kaolin, calcium sulfate, inorganic salts (e.g., sodium chloride, sodium bicarbonate}, acids such as citric acid, powdered cellulose derivatives, microcrystalline cellulose, silicified microcrystalline cellulose, fast dissolving carbohydrates such as PharmaburstT"', tribasic calcium phosphate, ammonium bicarbonate, calcium sulfate, magnesium carbonate, magnesium oxide, poloxamers which are closely related block copolymers of ethylene oxide and propylene oxide, hydroxypropyl methylcellulose, pullulan, gelatin, carrageenan, gums, combinations thereof, and other similar excipients known to those of skill in the art.
To ensure content uniformity of the blend, a volume mean diameter drug substance particle size of less than or equal to about 60 microns is utilized, more preferably less than or equal to about 40 microns and most preferable less than or equal to about 30 microns.
Preferred diluents are mannitol, sorbitol, xylitol, microcrystalline cellulose (e.g., Avicel(D PH200, PH102 or PH101 available from FMC BioPolymer, Philadelphia, PA), silicified microcrystalline cellulose (such as Prosolv available from PenWest Pharmaceuticals Co., Patterson, NY), cellulosic polymers such as hydroxypropyl methylcellulose (HPMC) and hydroxypropyl cellulose (HPC), pullulan and fast dissolving carbohydrates (such as PharmaburstTA available from SPI Pharma, New Castle, DE). Finally, examples of glidants include, but are not limited to, silicon dioxide, colloidal silicon dioxide, calcium silicate, magnesium silicate, magnesium trisilicate, talc, starch, combinations thereof, and any, other similar glidants known to those of skill in the art.
In any of the embodiments, a binder can be added. Suitable binders include, but are not limited to, substances such as celluloses (e.g., cellulose, methylcellulose, ethylcellulose, hydroxypropyl cellulose and hydroxypropyl methylcellulose), polypropylpyrrolidone, polyvinylprrolidone, gelatin, polyethylene glycol, starch, sugars, trehalose, glucose, sorbitol, natural and synthetic gums (e.g., acacia, alginates, carrageenan, xanthan gum, locust bean gum and gum arabic), waxes, combinations thereof, and any other binder substances known to those of skill in the art.
Further, in any of the embodiments, a lubricant can be used in a tablet formulation to prevent the tablet and punches from sticking in the die. Suitable lubricants include, but are not limited to calcium stearate, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, poloxamer, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, zinc stearate, combinations thereof, and any other suitable lubricants known to those of skill in the art. A preferred lubricant is magnesium stearate. The magnesium stearate is generally present in an amount from about 0.25 wt% to about 4.0 wt%.
Additionally, in any of the embodiments, disintegrants can also be added to the composition to break up the dosage form and release the compound. Suitable disintegrants include, but are not limited to, sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, alginic acid, chitosan, methyl cellulose, microcry,stalline cellulose, powdered cellulose, lower alkyl-substituted hydroxypropyl cellulose, polacrilin potassium, starch, pregelatinized starch, sodium alginate, combinations thereof, and any, other similar disintegrants known to those of skill in the art. Of these, crospovidone, croscarmellose sodium and sodium starch glycolate are preferred, with croscarmellose sodium being most preferred. The croscarmellose sodium is generally present in an amount from about 0.5 wt% to about 6.0 wt%.
Generally, the disintegrant comprises from 1wt% to 15wt%, preferably from 1 wt% to 10 wt% of the dosage form.
In any of the embodiments, a flavor or sweetener can be added. Flavors can be chosen from natural and synthetic flavors. Flavors useful in the present invention include, but are not limited to, volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins or extracts derived from plants, leaves, flowers, fruits, stems, combinations thereof, and other similar flavors known to those of skill in the art. These may include cinnamon oil, oil of wintergreen, peppermint oils, clove oil, bay oil, anise oil, eucalyptus, thyme oil, cedar leaf oil, oil of nutmeg, oil of sage, oil of bitter almonds, and cassia oil. Further oils include, but are not limited to, citrus oils such as lemon, orange, grape, lime and grapefruit and fruit essences including apple, pear, peach, grape, strawberry, raspberry, cherry, plum, pineapple, apricot, and other fruit flavors. Other useful flavorings include, but are not limited to, vanilla, aldehydes and esters such as benzaidehyde (cherry, almond), citral, i.e., alphacitral (lemon, lime), neral, i.e., betal-citral (lemon, lime), decanal (orange, lemon), aldehyde C-8 (citrus fruits), aidehyde C-9 (citrus fruits), aldehyde C-12 (citrus fruits), tolyl aldehyde (cherry, almond), 2,6-dimethyloctanal (green fruit), and 2-dodecenal (citrus, mandarin), combinations thereof, and other similar flavorings known to those of skill in the art.
Sweeteners that can be used with any embodiment of the present invention include, but are not limited to, corn syrup, dextrose, invert sugar, fructose, and mixtures thereof;
saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; sugar alcohols such as sorbitol, mannitol, zylitol;
and the like. Also contemplated are hydrogenated- starch hydrolysates and synthetic sweetener 3,6-dihydro-6-methyi-1-1-1,2,3- oxathiazin-4-one-2,2-dioxide, particularly the potassium salt (acesulfame-K) and sodium and calcium salts thereof, and any other sweeteners known to those of skill in the art.
Other ingredients such as colorants and titanium dioxide can also be included.
In one embodiment of the present invention, the present invention provides a fast disintegrating dosage form of varenicline comprising an effective amount of varenicline or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. The dosage form disintegrates in a patient's oral cavity in less than three minutes.
The fast-disintegrating dosage form of varenicline is a solid dosage form that does not require water to aid swallowing. Oral fast-disintegrating products have the potential of improving the overall clinical performance of a drug by reducing the incidence of non-compliance. A patient who is busy or traveling is more likely to take an oral fast-disintegrating dosage form, than a standard tablet requiring water. The phrase "completely disintegrate, dissolve or disperse"
used in the context of the present invention, means the FDDF dissolves or disintegrates to an extent that the patient believes the solid dosage form to be completely dissolved or disintegrated. That is, the patient can no longer detect any significant lumps or large particles of the original solid dosage form. Instead, at the point in time when the solid dosage from has completely dissolved or disintegrated in the oral cavity of the patient.
These fast disintegrating dosage forms are typically tablets and thin films that dissolve or disperse rapidly when in contact with saliva. In accordance with the present invention, fast disintegrating dosage forms of varenicline dissolve or disintegrate in the oral cavity following administratiori in a time range from about two seconds to about three minutes.
More preferably, disintegration occurs from about two seconds to two minutes, and most preferably from about two seconds to about one minute. The saliva containing the dissolved or dispersed active ingredient is then swallowed.
The preferred formulations of the present invention contain less than about 20% wt reducing carbohydrates. The presence of reducing carbohydrates is detrimental to the drug stability on storage. Reducing carbohydrates are sugars and their derivatives that contain a free aldehyde or ketone group capable of reaction with the secondary amine of varenicline.
Examples of reducing carbohydrates include, but are not limited to, monosaccharides, disaccharides, lactose, glucose, fructose, maltose, and other similar sugars known to those of skill in the art. Further, formulations containing dicalcium phosphate are particularly stable.
More specifically, stable formulations are produced with more than about 20 wt% dicalcium phosphate.
The compositions of the present invention can be prepared utilizing numerous technologies including, but not limited to, spray drying, freeze-drying, heat molding and disintegrant-based and/or sugar-based excipient addition, sublimation, and consumable thin film manufacture.
Spray-drying is a widely used process in the pharmaceutical industry and- can be used to produce highly porous compositions of varenicline. Spray-dried varenicline, as its free base or its suitable salt derivatives, is combined with excipients including, but not iimited to bulking agents such as mannitol, disintegrants such as sodium starch glycolate and croscarmellose sodium, acidic ingredients such as citric acid, glidants and lubricants. This mixture can be blended, granulated, and compressed into tablets as described herein.
Examples of such methods for other drugs are set forth in U.S. Patent Nos.
5,587,180, 5,595,761, 5,635,210, and 5,807,576, each of which is hereby incorporated by reference in its entirety.
The process for spray drying varenicline includes the steps of: (a) dissolving varenicline in a spray solution including a suitable solvent and (b) rapidly evaporating the solvent. Suitable solvents are those that varenicline is soluble including, but not limited to, hydroxylic solvents, non-hydroxylic solvents, water, acetone, tetrahydrofuran, methanol, ethanol, isomeric propanols, combinations thereof, and any other suitable solvents known to those of skill in the art. Alternatively, as varenicline is a low dose drug it could be spray dried with one or more non-volatile excipients as a carrier.
Varenicline should have a solubility of at least 1 wt%, and more preferably at least 5 wt% in the selected solvent. Preferably, the solvent is also volatile with a boiling point of 150 C or less. In addition, the solvent should have relatively low toxicity and be removed from the varenicline to a level that is acceptable according to the International Committee on Harmonization (ICH) guidelines. Removal of solvent to this level can require a subsequent processing step such as tray-drying or fluid bed drying.
In a preferred method, varenicline is spray dried with one or more excipients as a carrier. The rapid evaporation of spray drying achieves yet another advantage, which is the formation of particles having relatively uniform particle size distribution and shape. The particles formed by rapid evaporation have better flow characteristics and are iess likely to become segregated during manufacturing, such as during handling to form tablets. This is particularly important for a drug such as varenicline, since the drug itself has a high potency and therefore is used at a low dose. Reducing segregation during manufacture of the dosage form is important to ensure uniformity of dose in the dosage form. Thus, spray-drying reduces segregation during manufacturing of the dosage form by providing varenicline in a form that is easier to handle. Once the varenicline-containg spray, dried composition has been formed, several processing operations can be used to facilitate incorporation of the varenicline into a dosage form. These processing operations include drying, granulation, milling, compression, and the like.
In another embodiment of the present invention, effervescent excipients are incorporated into a varenicline solid dosage form. Once the dosage form is placed in the patient's oral cavity, contact with saliva promotes the acid-base reaction leading to rapid disintegration and release of the active varenicline. The effervescent sensation is not only pleasant to the patient, but also tends to stimulate saliva production, thereby providing additional water to aid in further effervescence and disintegration. Thus, once the dosage form (usually a tablet) is placed in the patient's mouth, it can disintegrate rapidly and completely without any voluntary action by the patient. Even if the patient does not chew the tablet, disintegration proceeds rapidly. Upon disintegration of the tablet, the active varenicline is released and can be swallowed as a slurry or suspension or it can dissolve in the saliva prior to swallowing. The varenicline can be in the form of a powder or it can be in microparticulate form with one or more excipients. The drug in microparticulate form is the preferred form as optionally it aids in taste-masking.
It is also preferred that the microparticles do not release the active varenicline in the oral cavity. Thus the varenicline can be transferred to the patient's stomach for dissolution in the digestive tract and systemic distribution of the pharmaceutical ingredient. In this way, the dosage form provides taste-masking.
The combination of the effervescent disintegration agent and the microparticles containing the varenicline provides an effective dosage form for systemic distribution. The microparticies can be relatively fragile microparticies susceptible to release of the pharmaceutical ingredient upon rupture of the microparticle. The tablet can disintegrate with minimal or no chewing, thus minimizing the problem of microparticle rupture.
The effervescent disintegration agent includes any compound that evolves gas. The preferred effervescent agents evolve gas by chemical reactions that take place upon exposure of the effervescent disintegration agent to water and/or to saliva in the mouth. The bubble or gas generating reaction is most often the result of the reaction of a soluble acid source such as citric acid and an alkali metal carbonate or carbonate source such as sodium bicarbonate and sodium carbonate. The reaction of these two general classes of compounds produces carbon dioxide gas upon contact with water included in saliva. The dosage form according to this aspect of the present invention can further include one or more additional excipients including flavors, diluents, colors, binders, fillers, and non-effervescent disintegrants and can be chosen from those herein described.
When varenicline is present in microparticles, the microparticle can be provided as a microcapsule or as a matrix-type microparticle. Microcapsules typically incorporate a discrete mass of the pharmaceutical ingredient surrounded by a discrete, separately observable coating of the protective material. Conversely, in a matrix-type particle, the pharmaceutical ingredient is dissolved or suspended throughout the protective material.
Certain microparticles can include attributes of both microcapsules and matrix-type particles. For example, a microparticle can incorporate a core by incorporating the pharmaceutical ingredient in first a protective material and then in a coating of a second protective material, which may be the same as or different from the first protective material surrounding the core.
Alternatively, a microparticle can incorporate a core including the pharmaceutical ingredient and a coating incorporating the protective material, wherein the coating.
itself has some of the pharmaceutical ingredient dispersed within it. These and other known microparticle configurations can be employed.
The microparticles desirably are between about 50 and 800 microns mean outside diameter, and more preferably between about 100 and about 250 microns. Other examples of methodsare set forth in U.S. Patent Nos. 6,210,711, 5,607,697, 5,178,878, 5,503,846, 4,414,198, 5,298,261, 5,188,825, 5,215,756, 5,298,261, 4,687,662, and 4,946,684, the contents of which are hereby incorporated herein by reference in their entirety.
In another embodiment of the present invention, there is provided a method of freeze-drying. Freeze-drying is a common method for preparing porous structures that dissolve rapidly. One embodiment is a freeze-dried tablet that can be produced by admixing a solvent, granular therapeutic agent, and a carrier material such as gelatin. A natural gum such as xanthan gum is then added to the liquid admixture because it behaves synergistically with gelatin as a flocculating agent to improve the ability of the liquid composition to suspend relatively large particles during the manufacturing process. The liquid composition is then placed into one or more shaped depressions in a tray or mold, and then freeze-dried.
Examples of such methods are set forth in U.S. Patent Nos. 6,680,071, 5,738,875, 6,509,040, 5,631,023, 5,843,347, 5,188,825, 4,946,684, 4,642,903, 4,371,516, 4,305,502 and 5,843,347 and PCT International Patent Publications WO 95/01782A2 and WO
00144351A1, the contents of which are hereby incorporated herein by reference in their entirety.
In yet another embodiment of the present invention, there is provided a heat molding method. Fast disintegrating dosage forms of varenicline can be prepared by a method that employs a heat-molding process that involves the steps of setting a molten composition of varenicline. One embodiment consists of an agar solution of a non-reducing sugar such as mannitol as a binder. Examples of such methods are set forth in U.S. Patent Nos. 6,375,982, 6,406,717, 5,466,464, and 5,853,758, the contents of which are hereby incorporated herein by reference in their entirety.
A preferred method of preparing a rapid-melt, semi-solid molded composition of varenicline or its suitable salt derivative includes the following steps:
a) melting at least one binder such as lipid materials, polyethylene glycols (PEG}, waxes and other fats such as cocoa butter in an amount from about 0.01 % to about 70% by weight with a salivating agent such as xylitol, sorbitan monostearate, or polyoxyethylene sorbitan ester in an amount from about 0.05% to about 15% by weight, to form a mixture;
b) mixing a therapeutically effective amount of varenicline with the mixture to form an active mixture;
c) mixing additional excipients such as silicon dioxide, starches, sorbitol, fructose, magnesium stearate, dicalcium phosphate, xylitol, mannitol, maltitol, isomalt, celluloses and mixtures with the active mixture to form a final mixture; and d) molding the final mixture into the rapid-melt, semi-solid molded composition.
The rapid-melt, semi-solid molded compositions can contain at least one binder, a salivating agent, an active material, and a diluent/bulking material.
The combination of excipients allows for fast disintegration of the composition when placed in the mouth of a patient. By pressing the composition on or under the tongue, or between the tongue and cheek of the user, the saliva of the user provides hydration to the composition and allows the composition to disintegrate with little or no chewing. The composition becomes a liquid upon the application of pressure. The semi-solid compositions rapidly disintegrate upon the application of pressure by the tongue of the patient, thus forming a liquid carrier for the active ingredients contained therein. The liquid helps provide the unique characteristics and features of the present inventive compositions.
The rapid-disintegrating, semi-solid compositions of the present invention can include at least one binder. As used herein, "binder" means at least one ingredient useful in keeping the composition in its semi-solid state, and can include, without limitation, a high melting point fat or waxy material such as lipid materials, polyethylene glycols (PEG), waxes, and other fats. Preferably, the semi-solid compositions of the present inventive subject matter include a mixture of binders. The binders useful in the compositions of the present inventive subject matter have a melting point of about 25 to 90 C., and preferably about 37 C.
When more than one binder is used in the compositions of the present invention, the melting point of the combination of the binders remain within the range of 25 to 90 C, and preferably, about 37 C.
The present invention uses mixtures of binders. Among the lipid materials useful as binders in the compositions of the present inventive subject matter are those that are commercially available and commonly used in confectionery and other food products. Such lipid materials include, without limitation, cocoa butter, hydrogenated tallow, hydrogenated vegetable oils, hydrogenated cotton seed oil, palm kernel oil, soybean oil, olive oil, stannol esters, and derivatives and mixtures thereof. Hydrogenated vegetable oils (such as hydrogenated palm kernel oil), cocoa butter, and cocoa butter substitutes are among the preferred useful lipid materials.
The amount of binder present in the rapid-disintegrating, semi-solid molded composition of the present invention is from about 0.01% to about 70% by weight of the final composition. Preferably, the amount of binder is from about a.01 % to about 50% by weight of the composition. More preferably the binder is present from about 15% to about 30% by weight of the composition. The rapid-disintegrating, semi-solid molded composition of the present invention can also contain a salivating agent. As is used herein, "salivating agent"
means a material that promotes greater salivation in the user of the compositions of the present inventive subject matter. The salivating agent helps create salivation in the mouth of the patient using the compositions of the present invention. This is an important feature since the compositions of the present invention are intended to be taken by the patient without the aid of water to help in the transporting of the composition to the stomach of the patient. The salivating agent can be, without limitation, an emulsifier or a food acid that initiates salivation in the mouth of the patient. Examples of emulsifiers useful as salivating agents in the compositions of the present invention include, but are not limited to, alkyl aryl sulfonates, alkyl sulfates, sulfonated amides and amines, sulfated and sulfonated esters and ethers, alkyl sulfonates, polyethoxlyated esters, mono- and diglycerides, diacetyl tartaric esters of monoglycerides, polyglycerol esters, sorbitan esters and ethoxylates, lactylated esters, phospholipids such as lecithin, polyoxyethylene sorbitan esters, proplyene glycol esters, sucrose esters, combinations thereof, and other similar emulsifiers known to those of skill in the art. The emulsifier can be either saturated or unsaturated. Examples of food- acids useful as salivating agents in the inventive compositions include, without limitation, citric acid, malic acid, food salts such as sodium chloride and salt substitutes, potassium chloride, combinations thereof, and other similar food acids known to those of skill in the art.
The amount of salivating agent present in the rapid-melt, semi-solid molded composition of the present invention is from about 0.05% to about 30% by weight of the final composition. Preferably, the amount of salivating agent is from about 0.3% to 20% by weight of the composition. Keeping the amount of salivating, agent present in the inventive composition within these limits for weight percentage is important to enhance the desirable properties of the compositions. More particularly, the low amount of salivating agent present in the compositions aids in the compositions retaining the semi-solid state and the rapidity of melting in the mouth of a patient.
The rapid-disintegrating, semi-solid molded compositions of the present invention can further contain additional excipients to aid in the moisturizing of the composition when chewed. That is, the additional excipients aids in the processability of the compositions. The additional excipients can also serve to reduce the concentration of the active materials and add bulk to the composition. Examples of additional excipients useful in the compositions of the present invention include, but are not limited to, silicon dioxide, sugars, starches, sucrose, sorbitol, fructose, talc, stearic acid, magnesium stearate, dicalcium phosphate, erythitol, xylitol, mannitol, maltitol, isomalt, dextrose, maltose, microcrystalline celluloses, combinations thereof, and other similar additional excipients known to those of skill in the art.
The amount additional excipients present in the semi-solid molded compositions is from about 10% to about 90% by weight of the final composition. Preferably, the amount of additional excipients is from about 35% to about 55% by weight of the final composition.
The use of flavors and sweeteners to mask the taste of the active materials can be used with the compositions of the present invention. Thus, other materials, which can be incorporated into the rapid-melt, semi-solid molded composition of the present inventive subject matter include flavors, colors and sweeteners. A distinct feature of the rapid-melt, semi-solid compositions is that they exhibit excellent taste characteristics.
Importantly, it is possible to incorporate high levels of flavors; sweeteners and other taste-masking agents if desired. Flavors can be chosen from natural and synthetic flavors. Flavors useful in the present invention include, but are not limited to, volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins or extracts derived from plants, leaves, flowers, fruits, stems, combinations thereof, and other similar flavors known to those of skill in the art.
Further oils include, but are not limited to, citrus oils such as lemon, orange, grape, lime and grapefruit and fruit essences including apple, pear, peach, grape, strawberry, raspberry, cherry, plum, pineapple, apricot, and other fruit flavors. Other useful flavorings include, but are not limited to, mint, peppermint, cinnamon, wintergreen, vanilla, aldehydes and esters such as benzaldehyde (cherry, almond), citral, i.e., alphacitral (lemon, lime), neral, i.e., betal-citral (lemon, lime), decanal (orange, lemon}, aidehyde C-8 (citrus fruits), aldehyde C-9 (citrus fruits), aldehyde C-12 (citrus fruits), tolyl aldehyde (cherry, almond), 2,6-dimethyloctanal (green fruit), and 2-dodecenal (citrus, mandarin), combinations thereof, and other similar flavorings known to those of skill in the art.
Sweeteners that can be used with any embodiment of the present invention include, but are not limited to, corn syrup, dextrose, invert sugar, fructose, and mixtures thereof;
saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia rebaudiana (Stevioside); chloro derivatives, of sucrose such as sucralose; sugar alcohols such as sorbitol, mannitol, zylitol;
and the like. Also contemplated are hydrogenated starch hydrolysates and synthetic sweetener 3,6-dihydro-6-methyl-1-1-1,2,3- oxathiazin-4-one-2,2-dioxide, particularly the potassium salt (acesulfame-K) and sodium and calcium salts thereof, and any other sweeteners known to those of skill in the art.
It should be recognized that the composition can be prepared by a variety of methods well-known by those of ordinary skill in the art. Such processes can be used on a batch or continuous process format and involve melting the binders and uniformly blending them for suitable periods of time prior to adding the salivating agent. Once these two components have been blended together, further components can be added either together or sequentially until a uniform mixture is obtained. The resulting mixture is in a semi-solid state that can be poured into a mold, cast into preformed shapes, or stamped into the final products. Other tableting techniques can be used.
In a further embodiment of the present invention, there is provided a disintegrant-based fast disintegrating dosage form. Disintegrants in fast dissolving dosage forms affect the rate of tablet disintegration and therefore the dissolution of varenicline. They are widely used in the development of fast-dissolving tablets. Examples of preferred disintegrants suitable for formulating with varenicline include, but are not limited to, sodium starch glycolate and croscarmellose sodium, starch, microcrystalline cellulose, substituted hydroxypropyl cellulose, crosslinked polyvinylpyrrolidone and modified cellulose. Additional disintegrants and such methods to formulate them with the active drug, varenicline, are set forth in European Patent No. EP 1 194 125; PCT International Patent Publication No. WO
01/03672;
U.S. Patent Application Publication No. 2002/0068084A1; and, U.S. Patent Nos.
5,464,632, 5,178,878, 5,503,846, 6,391,335, 6,200,604, 6,365,182, 5,298,261, 5,215,756, 4,371,516, 4,305,502, and 4,946,684, the contents of which are hereby incorporated herein by reference in their entirety.
Another embodiment of the present invention provides a carbohydrate-based fast dissolving dosage form. Using this technology varenicline formulations include a co-processed carbohydrate system and suitable excipients. These formulations are directly compressible into solid dosage forms that rapidly and completely dissolve and/or disintegrate in the oral cavity, preferably within about sixty seconds. The co-processed carbohydrates, and formulations produced therefrom, include particles having a non-filamentous microstructure. The co-processed carbohydrates and the formulations produced therefore are directly compressible into solid dosage forms. The term "co-processed carbohydrate"
means the processing of at least two polyols together to make a single product. For example, mannitol and sorbitol can be co-spray dried by first preparing a single solution of mannitol and sorbitol. Co-processing of carbohydrates includes, co-granulating at least two granular or crystalline polyols such as mannitol and sorbitol, co-granulating at least two spray-dried polyols, or co-granulating a spray-dried polyol and a granular or crystalline polyol. Co-processing also includes, but is not limited to, co-spray drying at least two polyols. Examples and means are set forth in U.S. Patent No. 6,497,899, the contents of which are hereby incorporated by reference. The term "co-processed carbohydrate system" is construed to include a co-processed carbohydrate plus a disintegrant and a glidant.
In one embodiment, a co-processed carbohydrate system formulation of varenicline according to the present invention includes, but is not limited to, at least two co-processed carbohydrates, one or more disintegrating agents such as crospovidone, sodium croscarmellose, sodium starch glycolate, and combinations thereof, and one or more glidants herein before defined.
Carbohydrates useful in the present invention include, but are not limited to, sorbitol, mannitol, erythritol, maltitol, lactitol, isomalt, and mixtures thereof.
Examples and means are set forth in PCT International Patent Application No. W02003-051338. The contents of which are set forth as reference. The tablets produced by this method described in the reference above preferably have a tablet hardness in the range of about 10 newtons to about 100 newtons and a friability (standard USP test method) in the range of about 0.0 percent to about 5 percent.
A further embodiment of the present invention provides a sugar-based fast-dissolving dosage form. Typically these sugars act as bulking agents and often provide a pleasant mouth feel and taste masking. One or more sugar - based excipients from the following list may be formulated with varenicline to prepare a fast-disintegrating dosage form: amylose, dextrose, fructose, sucrose, erythritol, isomalt, lacitol, maltitol, mannitol, sorbitol, starch hydrolysate, polydextrose, glucose and xylitol. In particular, preferred formulations of varenicline using this technology contain less than about 20 wt% of the reducing sugars including lactose, glucose, fructose, maltose and other similar sugars.
Additional references to this technology and such methods to formulate them with an active drug are set forth in U.S. Patent Nos. 5,576,014, 6,589,554, 6,316,027, 6,277,406, 6,171,607, and 6,165,512, the contents of which are hereby incorporated herein by reference in their entirety.
Methods that convert a mixture of spinnable carrier sugars and other processing aids into candy floss are also useful to prepare fast-dissolving dosage forms of varenicline. The candy floss can be milled and blended with varenicline and other excipients and compressed into fast-dispersing tablets. The method can also be used to produce microspheres instead of floss and has applications in the production of fast-dissolving, chewable and sustained release tablets. Similarly, the methods to formulate them with the active drug, varenicline, are set forth in U.S. Patent Nos. 4,855,326; 5,587,172; 5,622,719; 5,869,098;
5,866,163; and, PCT International Patent Application Nos. Wg 95/34293A1 and WO 95/334290A1, the contents of which are hereby incorporated herein by reference in their entirety. The combination of varenicline with starch or cellulose and one or more water soluble saccharides such as erythritol produces aformulation that displays rapid disintegration as disclosed in Murakami, T Proc. Int. Symp. Controlled Bioact. Matter 1999, 26, 855-6. Other fast-dissolving formulation applications employing varenicline as the active pharmaceutical ingredient with high amylose containing starch or polymeric materials including, but not limited to, gelatin, dextran, and dextrin via a steam extruded process are disclosed in U.S. Patent No.
6,375,982, which is incorporated herein by reference in its entirety.
Another embodiment of the present invention provides a sublimation method.
Varenicline can be formulated using sublimation techniques to prepare highly porous compressed tablets. In this method, inert solid ingredients that volatize readily including, but not limited to, urea, ammonium bicarbonate, ammonium carbonate, hexamethylene tetramine, naphthalene, phthalic anhydride, benzoic acid, camphor, menthol are formulated with other excipients and compressed into a tablet. Volatile materials are then removed via sublimation, which generates a porous structure. For example, highly porous, rapidly dispersible tablets can be prepared by using mannitol as a tablet matrix and camphor as the subliming material.
Tablets prepared using sublimation techniques exhibit excellent mechanical strength and a high dissolution rate. Examples of such methods to formulate them with the active drug, varenicline, are set forth in US patents and are herein incorporated by reference in their entirety: US 3,885,026; 4,134,943; 5,762,961; 5,720,974; 5,529,789; US Patent Application 2002-0002172A1.
A further embodiment of the present invention provides a thin film delivery method.
Thin film (or "wafer") delivery systems of varenicline include stamp-size medicinal strips that quickly disintegrate and/or dissolve when placed in the oral cavity.
Typically, thin film dosage forms are based on hydrophilic polymers with film-forming properties. Fillers are used to modify the texture and to improve handling characteristics. Disintegration and release profiles are modified by the addition of disintegrants, amphiphilic substances or poorly soluble polymers. Additional excipients such as flavors and coloring agents are also incorporated. In one preferred embodiment thin film strips vary in thickness from about 30 microns to about 300 microns and can accommodate up to about 10 mg of drug for fast-disintegrating applications, and more preferably from about 40 microns to about 200 microns and can accommodate up to about 5 mg of drug for fast-dissolve applications. In another embodiment the dosage size of the varenicline dosage filmstrip is between 5 to 20 cm2 more preferably the dosage film strip is between 3 to 15 cm2 and most preferably the dosage film strip is between 1 to 8 cm2. The thin film varenicline dosage form can be single or multi-layered, soft and elastic or hard and stiff, smooth-faced or possess a fibrous texture. More preferably, the thin film varenicline dosage form includes a single layer that is soft, elastic, and smooth faced and has a pleasant mouth feel.
Most thin film dosage forms can be produced by, any methods known to those of skill in the art including, but not limited to, film coating, casting technology, extrusion technology, and the like. For example, thin film wafers containing varenicline can be manufactured by first preparing a polymeric solution or suspension from the varenicline and inactive excipients.
Next the solution or suspension is evenly coated onto a process foil. A multi-stage drying process then removes solvents and solvent residuals. Such methods are set forth in U.S.
Patent Nos. 6,284,264, 6,1771,096, 6,153,222, and 5,948,430, the contents of which are incorporated herein by reference in their entirety. Other methods of producing fast disintegrating dosage forms that are films including varenicline are disclosed below: U.S.
Patent Nos. 6,596,298, 6,552,024, and 6,596,298; and, PCT International Patent Publication Nos. WO 00/18365, WO 01/70194, WO 03/011259, and WO 02/43657, the contents of which are herein incorporated by reference in their entirety.
The film-forming agent used in the films according to the present invention includes, but is not limited to, pullulan, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, xanthan gum, tragacanth gum, guar gum, acacia gum, arabic gum, locust bean gum, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl polymer, amylose, high amylose starch, hydroxypropylated high amylose starch, dextrin, pectin, chitin, chitosan, levan, elsinan, collagen, gelatin, zein, gluten, soy protein isolate, whey protein isolate, casein and mixtures thereof. A preferred film former is pullulan, in amounts ranging from about 0.01 to about 99 wt%, preferably about 30 to about 80 wt%, more preferably from about 45 to about 70 wt% of the film and even more preferably from about 60 to about 65 wt / of the film.
The film of the invention preferably includes pullulan as a film-forming agent and can further include water, additional film-forming agents, plasticizing agents, additional flavoring agents, saliva stimulating agents, cooling agents, surfactants, stabiiizing agents, emulsifying agents, thickening agents, binding agents, coloring agents, sweeteners, fragrances, and the like.
Useful saliva stimulating agents are those disclosed herein above for heat-molding processes and in U.S. Pat. No. 4,820,506, which is incorporated herein by reference in its entirety. Saliva stimulating agents include, but are not limited to, food acids such as citric, lactic, malic, succinic, ascorbic, adipic, fumaric and tartaric acids.
Preferred food acids are citric, malic and ascorbic acids. The amount of saliva stimulating agents in the film is from about 0.01 to about 12 wt%, preferably about 1 to about 10 wt%, and even more preferably about 2.5 to about 6 wt%. Preferred plasticizing agents include triacetin in amounts ranging from about 0 to about 20 wt%, preferably about 0 to about 2 wt%. Other suitable plasticizing agents include monoacetin and diacetin.
Preferred cooling agents include monomenthyl succinate, in amounts ranging from about 0.001 to about 2.0 wt%, preferably about 0.2 to about 0.4 wt%. A
monomenthyl succinate containing cooling--agent is available from Mane, Inc. Other suitable cooling agents include WS3, WS23, Ultracool II and the like. Preferred surfactants include mono and diglycerides of fatty acids and polyoxyethylene sorbitol esters, such as, Atmos 300 and Polysorbate 80. The surfactant can be added in amounts ranging from about 0.5 to about 15 wt%, preferably about 1 to about 5 wt% of the film. Other suitable surfactants include, but are not limited to, poloxamers (Pluronic@)) available from BASF Corporation, Florham Park, NJ), sodium lauryl sulfate, docusate sodium and the like.
Preferred stabilizing agents include xanthan gum, locust bean gum, and carrageenan, in amounts ranging from about 0 to about 10 wt%, preferably about 0.1 to about 2 wt% of the film. Other suitable stabilizing agents include guar gum and the like.
Preferred suspending agents include, but are not limited to, triethanolamine stearate, quaternary ammonium compounds, acacia, gelatin, lecithin, bentonite, Veegum available from R.T.
Vanderbilt, Norwalk, CT, and the like, in amounts ranging from about 0 to about 5 wt%, preferably about 0.01 to about 0.7 wt% of the film.
Preferred thickening agents include methylcellulose, carboxyl methylcellu lose, hydroxymethyl propylcellulose and the like, in amounts ranging from about 0 to about 20 wt%, preferably about 0.01 to about 5 wt%. Preferred binding agents include starch, in amounts ranging from about 0 to about 10 wt%, preferably about 0.01 to about 2 wt% of the film.
Suitable sweeteners that can be included are those well known in the art and have been listed previously. The compositions of this invention can also contain coloring agents or colorants. The coloring agents are used in amounts effective to produce the desired color.
In certain methods for preparing films according to the invention, the film-forming ingredients are mixed and hydrated with water separately from the water-soluble ingredients, which are mixed in aqueous solution separately from the organic ingredients and surfactants.
In these methods, the final formulation is preferably produced by mixing the film-forming phase with the aqueous phase, then mixing in the organic phase, which includes surfactants, such as Polysorbate 80 and Atmos 300. This mass is mixed until emulsified. In other embodiments, the aqueous and film forming phases are combined into a single phase by dissolving the water-soluble ingredients in the water and then adding the gums to hydrate.
The organic phase is then added to this single aqueous phase.
saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia rebaudiana (Stevioside); chloro derivatives, of sucrose such as sucralose; sugar alcohols such as sorbitol, mannitol, zylitol;
and the like. Also contemplated are hydrogenated starch hydrolysates and synthetic sweetener 3,6-dihydro-6-methyl-1-1-1,2,3- oxathiazin-4-one-2,2-dioxide, particularly the potassium salt (acesulfame-K) and sodium and calcium salts thereof, and any other sweeteners known to those of skill in the art.
It should be recognized that the composition can be prepared by a variety of methods well-known by those of ordinary skill in the art. Such processes can be used on a batch or continuous process format and involve melting the binders and uniformly blending them for suitable periods of time prior to adding the salivating agent. Once these two components have been blended together, further components can be added either together or sequentially until a uniform mixture is obtained. The resulting mixture is in a semi-solid state that can be poured into a mold, cast into preformed shapes, or stamped into the final products. Other tableting techniques can be used.
In a further embodiment of the present invention, there is provided a disintegrant-based fast disintegrating dosage form. Disintegrants in fast dissolving dosage forms affect the rate of tablet disintegration and therefore the dissolution of varenicline. They are widely used in the development of fast-dissolving tablets. Examples of preferred disintegrants suitable for formulating with varenicline include, but are not limited to, sodium starch glycolate and croscarmellose sodium, starch, microcrystalline cellulose, substituted hydroxypropyl cellulose, crosslinked polyvinylpyrrolidone and modified cellulose. Additional disintegrants and such methods to formulate them with the active drug, varenicline, are set forth in European Patent No. EP 1 194 125; PCT International Patent Publication No. WO
01/03672;
U.S. Patent Application Publication No. 2002/0068084A1; and, U.S. Patent Nos.
5,464,632, 5,178,878, 5,503,846, 6,391,335, 6,200,604, 6,365,182, 5,298,261, 5,215,756, 4,371,516, 4,305,502, and 4,946,684, the contents of which are hereby incorporated herein by reference in their entirety.
Another embodiment of the present invention provides a carbohydrate-based fast dissolving dosage form. Using this technology varenicline formulations include a co-processed carbohydrate system and suitable excipients. These formulations are directly compressible into solid dosage forms that rapidly and completely dissolve and/or disintegrate in the oral cavity, preferably within about sixty seconds. The co-processed carbohydrates, and formulations produced therefrom, include particles having a non-filamentous microstructure. The co-processed carbohydrates and the formulations produced therefore are directly compressible into solid dosage forms. The term "co-processed carbohydrate"
means the processing of at least two polyols together to make a single product. For example, mannitol and sorbitol can be co-spray dried by first preparing a single solution of mannitol and sorbitol. Co-processing of carbohydrates includes, co-granulating at least two granular or crystalline polyols such as mannitol and sorbitol, co-granulating at least two spray-dried polyols, or co-granulating a spray-dried polyol and a granular or crystalline polyol. Co-processing also includes, but is not limited to, co-spray drying at least two polyols. Examples and means are set forth in U.S. Patent No. 6,497,899, the contents of which are hereby incorporated by reference. The term "co-processed carbohydrate system" is construed to include a co-processed carbohydrate plus a disintegrant and a glidant.
In one embodiment, a co-processed carbohydrate system formulation of varenicline according to the present invention includes, but is not limited to, at least two co-processed carbohydrates, one or more disintegrating agents such as crospovidone, sodium croscarmellose, sodium starch glycolate, and combinations thereof, and one or more glidants herein before defined.
Carbohydrates useful in the present invention include, but are not limited to, sorbitol, mannitol, erythritol, maltitol, lactitol, isomalt, and mixtures thereof.
Examples and means are set forth in PCT International Patent Application No. W02003-051338. The contents of which are set forth as reference. The tablets produced by this method described in the reference above preferably have a tablet hardness in the range of about 10 newtons to about 100 newtons and a friability (standard USP test method) in the range of about 0.0 percent to about 5 percent.
A further embodiment of the present invention provides a sugar-based fast-dissolving dosage form. Typically these sugars act as bulking agents and often provide a pleasant mouth feel and taste masking. One or more sugar - based excipients from the following list may be formulated with varenicline to prepare a fast-disintegrating dosage form: amylose, dextrose, fructose, sucrose, erythritol, isomalt, lacitol, maltitol, mannitol, sorbitol, starch hydrolysate, polydextrose, glucose and xylitol. In particular, preferred formulations of varenicline using this technology contain less than about 20 wt% of the reducing sugars including lactose, glucose, fructose, maltose and other similar sugars.
Additional references to this technology and such methods to formulate them with an active drug are set forth in U.S. Patent Nos. 5,576,014, 6,589,554, 6,316,027, 6,277,406, 6,171,607, and 6,165,512, the contents of which are hereby incorporated herein by reference in their entirety.
Methods that convert a mixture of spinnable carrier sugars and other processing aids into candy floss are also useful to prepare fast-dissolving dosage forms of varenicline. The candy floss can be milled and blended with varenicline and other excipients and compressed into fast-dispersing tablets. The method can also be used to produce microspheres instead of floss and has applications in the production of fast-dissolving, chewable and sustained release tablets. Similarly, the methods to formulate them with the active drug, varenicline, are set forth in U.S. Patent Nos. 4,855,326; 5,587,172; 5,622,719; 5,869,098;
5,866,163; and, PCT International Patent Application Nos. Wg 95/34293A1 and WO 95/334290A1, the contents of which are hereby incorporated herein by reference in their entirety. The combination of varenicline with starch or cellulose and one or more water soluble saccharides such as erythritol produces aformulation that displays rapid disintegration as disclosed in Murakami, T Proc. Int. Symp. Controlled Bioact. Matter 1999, 26, 855-6. Other fast-dissolving formulation applications employing varenicline as the active pharmaceutical ingredient with high amylose containing starch or polymeric materials including, but not limited to, gelatin, dextran, and dextrin via a steam extruded process are disclosed in U.S. Patent No.
6,375,982, which is incorporated herein by reference in its entirety.
Another embodiment of the present invention provides a sublimation method.
Varenicline can be formulated using sublimation techniques to prepare highly porous compressed tablets. In this method, inert solid ingredients that volatize readily including, but not limited to, urea, ammonium bicarbonate, ammonium carbonate, hexamethylene tetramine, naphthalene, phthalic anhydride, benzoic acid, camphor, menthol are formulated with other excipients and compressed into a tablet. Volatile materials are then removed via sublimation, which generates a porous structure. For example, highly porous, rapidly dispersible tablets can be prepared by using mannitol as a tablet matrix and camphor as the subliming material.
Tablets prepared using sublimation techniques exhibit excellent mechanical strength and a high dissolution rate. Examples of such methods to formulate them with the active drug, varenicline, are set forth in US patents and are herein incorporated by reference in their entirety: US 3,885,026; 4,134,943; 5,762,961; 5,720,974; 5,529,789; US Patent Application 2002-0002172A1.
A further embodiment of the present invention provides a thin film delivery method.
Thin film (or "wafer") delivery systems of varenicline include stamp-size medicinal strips that quickly disintegrate and/or dissolve when placed in the oral cavity.
Typically, thin film dosage forms are based on hydrophilic polymers with film-forming properties. Fillers are used to modify the texture and to improve handling characteristics. Disintegration and release profiles are modified by the addition of disintegrants, amphiphilic substances or poorly soluble polymers. Additional excipients such as flavors and coloring agents are also incorporated. In one preferred embodiment thin film strips vary in thickness from about 30 microns to about 300 microns and can accommodate up to about 10 mg of drug for fast-disintegrating applications, and more preferably from about 40 microns to about 200 microns and can accommodate up to about 5 mg of drug for fast-dissolve applications. In another embodiment the dosage size of the varenicline dosage filmstrip is between 5 to 20 cm2 more preferably the dosage film strip is between 3 to 15 cm2 and most preferably the dosage film strip is between 1 to 8 cm2. The thin film varenicline dosage form can be single or multi-layered, soft and elastic or hard and stiff, smooth-faced or possess a fibrous texture. More preferably, the thin film varenicline dosage form includes a single layer that is soft, elastic, and smooth faced and has a pleasant mouth feel.
Most thin film dosage forms can be produced by, any methods known to those of skill in the art including, but not limited to, film coating, casting technology, extrusion technology, and the like. For example, thin film wafers containing varenicline can be manufactured by first preparing a polymeric solution or suspension from the varenicline and inactive excipients.
Next the solution or suspension is evenly coated onto a process foil. A multi-stage drying process then removes solvents and solvent residuals. Such methods are set forth in U.S.
Patent Nos. 6,284,264, 6,1771,096, 6,153,222, and 5,948,430, the contents of which are incorporated herein by reference in their entirety. Other methods of producing fast disintegrating dosage forms that are films including varenicline are disclosed below: U.S.
Patent Nos. 6,596,298, 6,552,024, and 6,596,298; and, PCT International Patent Publication Nos. WO 00/18365, WO 01/70194, WO 03/011259, and WO 02/43657, the contents of which are herein incorporated by reference in their entirety.
The film-forming agent used in the films according to the present invention includes, but is not limited to, pullulan, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, xanthan gum, tragacanth gum, guar gum, acacia gum, arabic gum, locust bean gum, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl polymer, amylose, high amylose starch, hydroxypropylated high amylose starch, dextrin, pectin, chitin, chitosan, levan, elsinan, collagen, gelatin, zein, gluten, soy protein isolate, whey protein isolate, casein and mixtures thereof. A preferred film former is pullulan, in amounts ranging from about 0.01 to about 99 wt%, preferably about 30 to about 80 wt%, more preferably from about 45 to about 70 wt% of the film and even more preferably from about 60 to about 65 wt / of the film.
The film of the invention preferably includes pullulan as a film-forming agent and can further include water, additional film-forming agents, plasticizing agents, additional flavoring agents, saliva stimulating agents, cooling agents, surfactants, stabiiizing agents, emulsifying agents, thickening agents, binding agents, coloring agents, sweeteners, fragrances, and the like.
Useful saliva stimulating agents are those disclosed herein above for heat-molding processes and in U.S. Pat. No. 4,820,506, which is incorporated herein by reference in its entirety. Saliva stimulating agents include, but are not limited to, food acids such as citric, lactic, malic, succinic, ascorbic, adipic, fumaric and tartaric acids.
Preferred food acids are citric, malic and ascorbic acids. The amount of saliva stimulating agents in the film is from about 0.01 to about 12 wt%, preferably about 1 to about 10 wt%, and even more preferably about 2.5 to about 6 wt%. Preferred plasticizing agents include triacetin in amounts ranging from about 0 to about 20 wt%, preferably about 0 to about 2 wt%. Other suitable plasticizing agents include monoacetin and diacetin.
Preferred cooling agents include monomenthyl succinate, in amounts ranging from about 0.001 to about 2.0 wt%, preferably about 0.2 to about 0.4 wt%. A
monomenthyl succinate containing cooling--agent is available from Mane, Inc. Other suitable cooling agents include WS3, WS23, Ultracool II and the like. Preferred surfactants include mono and diglycerides of fatty acids and polyoxyethylene sorbitol esters, such as, Atmos 300 and Polysorbate 80. The surfactant can be added in amounts ranging from about 0.5 to about 15 wt%, preferably about 1 to about 5 wt% of the film. Other suitable surfactants include, but are not limited to, poloxamers (Pluronic@)) available from BASF Corporation, Florham Park, NJ), sodium lauryl sulfate, docusate sodium and the like.
Preferred stabilizing agents include xanthan gum, locust bean gum, and carrageenan, in amounts ranging from about 0 to about 10 wt%, preferably about 0.1 to about 2 wt% of the film. Other suitable stabilizing agents include guar gum and the like.
Preferred suspending agents include, but are not limited to, triethanolamine stearate, quaternary ammonium compounds, acacia, gelatin, lecithin, bentonite, Veegum available from R.T.
Vanderbilt, Norwalk, CT, and the like, in amounts ranging from about 0 to about 5 wt%, preferably about 0.01 to about 0.7 wt% of the film.
Preferred thickening agents include methylcellulose, carboxyl methylcellu lose, hydroxymethyl propylcellulose and the like, in amounts ranging from about 0 to about 20 wt%, preferably about 0.01 to about 5 wt%. Preferred binding agents include starch, in amounts ranging from about 0 to about 10 wt%, preferably about 0.01 to about 2 wt% of the film.
Suitable sweeteners that can be included are those well known in the art and have been listed previously. The compositions of this invention can also contain coloring agents or colorants. The coloring agents are used in amounts effective to produce the desired color.
In certain methods for preparing films according to the invention, the film-forming ingredients are mixed and hydrated with water separately from the water-soluble ingredients, which are mixed in aqueous solution separately from the organic ingredients and surfactants.
In these methods, the final formulation is preferably produced by mixing the film-forming phase with the aqueous phase, then mixing in the organic phase, which includes surfactants, such as Polysorbate 80 and Atmos 300. This mass is mixed until emulsified. In other embodiments, the aqueous and film forming phases are combined into a single phase by dissolving the water-soluble ingredients in the water and then adding the gums to hydrate.
The organic phase is then added to this single aqueous phase.
The resulting formulation is cast on a suitable substrate and dried to form a film. The film is preferably air-dried or dried under warm air and cut to a desired dimension, packaged and stored. The film can contain from about 0.1% to about 10 wt% moisture, preferably from about 3% to about 8 wt% moisture, even more preferably from about 4 to about 7 wt%
moisture.
The film-forming phase can include pullulan and stabilizing agents such as xanthan gum, locust bean gum and carrageenan. These ingredients are mixed and then hydrated in water for about 30 to about 48 hours to form a gel. The water is preferably heated to a temperature of about 25 to about 45 C. to promote hydration. The amount of water is about 40 to 80% of the gel. The resulting hydrated gel is then chilled to a temperature of about 20 to about 30 C. for about I to about 48 hours. The water is preferably deionized.
The aqueous phase can include ingredients such as coloring agent(s) and sweetener.
The water is preferably deionized and the amount of water used is about 5 to about 80 wt% of the final gel mixture. The films that deliver varenicline can also include a triglyceride.
Examples of triglycerides include vegetable oils such as corn oil, sunflower oil, peanut oil, olive oil, canola oil, soybean oil and mixtures thereof. A preferred triglyceride is olive oil. The triglyceride is added to the film in amounts from about 0.1 to about 12 wt%, preferably, in a range from about 0.5 to about 9 wt%, of the film. The films that contain varenicline also can include a preservative. The preservative is added in amounts from about 0.001 to about 5 wt%, preferably from about 0.01 to about 1 wt% of the film. Preferred preservatives include sodium benzoate and potassium sorbate.
The varenicline containing films can also include a polyethylene oxide compound.
The molecular weight of the polyethylene oxide compound ranges from about 50,000 to about 6,000,000. A preferred polyethylene oxide compound is Polyox WSR N-10 available from Dow Chemical Company, Midland, MI. The polyethylene oxide compound is added in amounts from about 0.1 to about 5 wt%, preferably from about 0.2 to about 4. 0 wt% of the film.
The varenicline containing films can also include propylene glycol. The propylene glycol is added in amounts from about 1 to about 20 wt%, preferably from about 5 to about 15 wt% of the film. The film can be coated to mask the taste of the active ingredient. The coatings that can be used are known to those skilled in the art. These include polymers such, as Eudragit E available from Rohm America L.L.C., Piscataway, NJ, cellulosics, such as ethylcellulose, and the like.
Additional ways to mask the taste of the active ingredient as known by those skilled in the art are hereby included. One such way is using an ion exchange resin such as Amberlite IRP-69, available from Rohm and Haas Co., Philadelphia, PA, and Dow XYS-40010.00, available from the Dow Chemical Co., Midland, MI.
moisture.
The film-forming phase can include pullulan and stabilizing agents such as xanthan gum, locust bean gum and carrageenan. These ingredients are mixed and then hydrated in water for about 30 to about 48 hours to form a gel. The water is preferably heated to a temperature of about 25 to about 45 C. to promote hydration. The amount of water is about 40 to 80% of the gel. The resulting hydrated gel is then chilled to a temperature of about 20 to about 30 C. for about I to about 48 hours. The water is preferably deionized.
The aqueous phase can include ingredients such as coloring agent(s) and sweetener.
The water is preferably deionized and the amount of water used is about 5 to about 80 wt% of the final gel mixture. The films that deliver varenicline can also include a triglyceride.
Examples of triglycerides include vegetable oils such as corn oil, sunflower oil, peanut oil, olive oil, canola oil, soybean oil and mixtures thereof. A preferred triglyceride is olive oil. The triglyceride is added to the film in amounts from about 0.1 to about 12 wt%, preferably, in a range from about 0.5 to about 9 wt%, of the film. The films that contain varenicline also can include a preservative. The preservative is added in amounts from about 0.001 to about 5 wt%, preferably from about 0.01 to about 1 wt% of the film. Preferred preservatives include sodium benzoate and potassium sorbate.
The varenicline containing films can also include a polyethylene oxide compound.
The molecular weight of the polyethylene oxide compound ranges from about 50,000 to about 6,000,000. A preferred polyethylene oxide compound is Polyox WSR N-10 available from Dow Chemical Company, Midland, MI. The polyethylene oxide compound is added in amounts from about 0.1 to about 5 wt%, preferably from about 0.2 to about 4. 0 wt% of the film.
The varenicline containing films can also include propylene glycol. The propylene glycol is added in amounts from about 1 to about 20 wt%, preferably from about 5 to about 15 wt% of the film. The film can be coated to mask the taste of the active ingredient. The coatings that can be used are known to those skilled in the art. These include polymers such, as Eudragit E available from Rohm America L.L.C., Piscataway, NJ, cellulosics, such as ethylcellulose, and the like.
Additional ways to mask the taste of the active ingredient as known by those skilled in the art are hereby included. One such way is using an ion exchange resin such as Amberlite IRP-69, available from Rohm and Haas Co., Philadelphia, PA, and Dow XYS-40010.00, available from the Dow Chemical Co., Midland, MI.
A further embodiment provides a method relating to taste masking. It is important that the fast dissolving dosage form of varenicline taste pleasant and have good mouth feel.
Flavor masking and processing approaches are the two primary methods=for achieving taste masking. Flavor masking includes the addition of flavors, sweeteners, acidic amino acids, lipids, and surfactants to attempt to overwhelm the unpleasant taste.
Processing approaches include microencapsulation with various cellulosic derivatives, polylactic acid, polyglycolic acid, polyvinyl alcohol, cellulose acetate phthalate, ethyl cellulose, resins and proteins, gelatinized starch, gums, cyclodextrins, chitosan, liposomes, and removal of bitter contaminants by ion exchange resins. Chemical modification and specific salt preparation of an active ingredient have also been used to reduce the unpleasant taste.
Microencapsulation processes can be used to taste mask actives and include both physical and chemical processes. Examples of some of these processes include, but are not limited to, coacervation, spray-drying, spray-chilling, spray-congealing, fluidization, phase separation, and extrusion.
Many taste masking technologies are compatible with fast dissolving dosage forms of varenicline or its suitable salt derivative. Disclosed below are taste masking methods suitable for these dosage forms: U.S. Patent Application Publication Nos. 2003-0170310A1, 2003-0124184, 2002-014701, 2003-0068376A1, 2003-0068378A1, 2003-0118653, 2003-0219479A1, and 2004-0013731; U.S. Patent Nos. 6,221,392, 5,607,697, 6,596,311, 6,589,556, 6,569,462, 6,451,345, 6,139,865, 5,709,886, 6,465,010, 6,284,270, and 6,552,024; European Patent Nos. EP 1 133 282, 1 007 012, and 1 194 125; WO
000197; and, PCT International Patent Publication Nos. WO 2003-059349, WO 2003-000229;
WO 02/02080; WO 02/02081, and WO 01/03672, the contents of which are hereby incorporated herein by reference in their entirety.
Other features and embodiments of the invention will become apparent from the following examples, which are given for illustration of the invention rather than for limiting its intended scope.
EXAMPLES
EXAMPLE 1: Co-processed carbohydrate Varenicline tartrate, 4g is blended together with equal amounts, 600 g each, of mannitol and sorbitol. The blend is put through a 14 mesh sieve. This blend is granulated in a fluidized-bed granulator using a 15 w/v % glucose solution as a binding agent. Initially the solution is sprayed at a pressure of 2.5 kg/cm 2; it is later reduced to 1.5 kg/cm 2. When the granulation is dry, other ingredients including a suitable flavor, such as peppermint flavor 10 g, and processing aids such as stearic acid 12 g, magnesium stearate 10 g are added to the granulation using a V-blender. The resultant granulation is compressed on a rotary tablet machine. The 540 mg tablets have average tablet hardnesses on the order of 1.5 kp. The tablets are humidified and heated for 20 minutes in a thermo-hygrostat at 35 C and 85% RH.
The tablets are dried for 15 minutes at 50 C and 30%RH. The tablet hardness increases to a hardness value of about 9 kp after the heat and humidity treatment.
EXAMPLE 2: Co-processed carbohydrate 3 Grams of varenicline tartrate and 324 g mannitol is blended and passed through a sieve (20 mesh). The blend is granulated in a fluidized-bed granulator with 100 g of a trehalose solution (20 w/v %) as a binding agent. After drying 0.5% magnesium stearate is mixed with the granulation. The granulation. is compressed on a rotary tablet press at a compression pressure of approximately 0.3 ton to produce 200 mg tablets having an average tablet hardness on the order of 1.5 kp. The tablets are stored under heated humidified conditions of 25 C/80%RH for 12 hours, using. a thermo-hygrostat and then they are dried for 2 hours at 30 C/40%RH. After the heat and humidity treatment, the tablets have a hardness of about 3 kp.
EXAMPLE 3: Tablets Prepared from Coated Varenicline Tartrate Microspheres and Floss Varenicline tartrate microspheres are made by a liquiflash process as described in U.S. Patent No. 5,683,720 using 85% varenicline tartrate, 7.5% carnauba wax and 7.5%
Pluronic F68. The Pluronic is milled using a FitzMill (The Fitzpatrick Co., Elmhurst, IL) with a 40 mesh screen. All of the ingredients are blended in a high sheer mixer for approximately 10 minutes. (The blend is then subjected to liquiflash processing at 60 Hz and 37% nominal power using the 5" V-groove heater head disclosed in U.S. Ser. No.
08/874,215-, filed Jun. 13, 1997.) The microspheres are sieved. The fraction passing through a 40 mesh and retained on 120 mesh sieve is coated in a fluid bed coater to a 30%
coating level using a 1:1 ethylcellulose:hydroxypropylcellulose coating solution dissolved in an acetone:isopropyl alcohol solvent for taste-masking.
Floss Preparation A preblend of 78.25% sucrose, 11.0% sorbitol, 10.0% xylitol and 0. 75%
polysorbate ' 80 (TweenTM 80, Uniqema, New Castle, DE) is prepared. The floss preblend is processed using the 5" crown head disclosed in U.S. Pat. No. 5,854,344, at a temperature of 250 C. and rotational speedof 60 Hz (3600 rpm). The floss collected is chopped in a high shear mixer with 2% lactose (2% w/w of the floss) for 2 minutes at 100 rpm with the choppers turned on.
Two-hundred proof ethanol (0.5% based on weight of the floss) is sprayed on the chopped floss and mixed. The floss is then dried at 45 C for 90 minutes with intermittent mixing. The dried, chopped floss is screened through a 20 mesh screen.
Flavor masking and processing approaches are the two primary methods=for achieving taste masking. Flavor masking includes the addition of flavors, sweeteners, acidic amino acids, lipids, and surfactants to attempt to overwhelm the unpleasant taste.
Processing approaches include microencapsulation with various cellulosic derivatives, polylactic acid, polyglycolic acid, polyvinyl alcohol, cellulose acetate phthalate, ethyl cellulose, resins and proteins, gelatinized starch, gums, cyclodextrins, chitosan, liposomes, and removal of bitter contaminants by ion exchange resins. Chemical modification and specific salt preparation of an active ingredient have also been used to reduce the unpleasant taste.
Microencapsulation processes can be used to taste mask actives and include both physical and chemical processes. Examples of some of these processes include, but are not limited to, coacervation, spray-drying, spray-chilling, spray-congealing, fluidization, phase separation, and extrusion.
Many taste masking technologies are compatible with fast dissolving dosage forms of varenicline or its suitable salt derivative. Disclosed below are taste masking methods suitable for these dosage forms: U.S. Patent Application Publication Nos. 2003-0170310A1, 2003-0124184, 2002-014701, 2003-0068376A1, 2003-0068378A1, 2003-0118653, 2003-0219479A1, and 2004-0013731; U.S. Patent Nos. 6,221,392, 5,607,697, 6,596,311, 6,589,556, 6,569,462, 6,451,345, 6,139,865, 5,709,886, 6,465,010, 6,284,270, and 6,552,024; European Patent Nos. EP 1 133 282, 1 007 012, and 1 194 125; WO
000197; and, PCT International Patent Publication Nos. WO 2003-059349, WO 2003-000229;
WO 02/02080; WO 02/02081, and WO 01/03672, the contents of which are hereby incorporated herein by reference in their entirety.
Other features and embodiments of the invention will become apparent from the following examples, which are given for illustration of the invention rather than for limiting its intended scope.
EXAMPLES
EXAMPLE 1: Co-processed carbohydrate Varenicline tartrate, 4g is blended together with equal amounts, 600 g each, of mannitol and sorbitol. The blend is put through a 14 mesh sieve. This blend is granulated in a fluidized-bed granulator using a 15 w/v % glucose solution as a binding agent. Initially the solution is sprayed at a pressure of 2.5 kg/cm 2; it is later reduced to 1.5 kg/cm 2. When the granulation is dry, other ingredients including a suitable flavor, such as peppermint flavor 10 g, and processing aids such as stearic acid 12 g, magnesium stearate 10 g are added to the granulation using a V-blender. The resultant granulation is compressed on a rotary tablet machine. The 540 mg tablets have average tablet hardnesses on the order of 1.5 kp. The tablets are humidified and heated for 20 minutes in a thermo-hygrostat at 35 C and 85% RH.
The tablets are dried for 15 minutes at 50 C and 30%RH. The tablet hardness increases to a hardness value of about 9 kp after the heat and humidity treatment.
EXAMPLE 2: Co-processed carbohydrate 3 Grams of varenicline tartrate and 324 g mannitol is blended and passed through a sieve (20 mesh). The blend is granulated in a fluidized-bed granulator with 100 g of a trehalose solution (20 w/v %) as a binding agent. After drying 0.5% magnesium stearate is mixed with the granulation. The granulation. is compressed on a rotary tablet press at a compression pressure of approximately 0.3 ton to produce 200 mg tablets having an average tablet hardness on the order of 1.5 kp. The tablets are stored under heated humidified conditions of 25 C/80%RH for 12 hours, using. a thermo-hygrostat and then they are dried for 2 hours at 30 C/40%RH. After the heat and humidity treatment, the tablets have a hardness of about 3 kp.
EXAMPLE 3: Tablets Prepared from Coated Varenicline Tartrate Microspheres and Floss Varenicline tartrate microspheres are made by a liquiflash process as described in U.S. Patent No. 5,683,720 using 85% varenicline tartrate, 7.5% carnauba wax and 7.5%
Pluronic F68. The Pluronic is milled using a FitzMill (The Fitzpatrick Co., Elmhurst, IL) with a 40 mesh screen. All of the ingredients are blended in a high sheer mixer for approximately 10 minutes. (The blend is then subjected to liquiflash processing at 60 Hz and 37% nominal power using the 5" V-groove heater head disclosed in U.S. Ser. No.
08/874,215-, filed Jun. 13, 1997.) The microspheres are sieved. The fraction passing through a 40 mesh and retained on 120 mesh sieve is coated in a fluid bed coater to a 30%
coating level using a 1:1 ethylcellulose:hydroxypropylcellulose coating solution dissolved in an acetone:isopropyl alcohol solvent for taste-masking.
Floss Preparation A preblend of 78.25% sucrose, 11.0% sorbitol, 10.0% xylitol and 0. 75%
polysorbate ' 80 (TweenTM 80, Uniqema, New Castle, DE) is prepared. The floss preblend is processed using the 5" crown head disclosed in U.S. Pat. No. 5,854,344, at a temperature of 250 C. and rotational speedof 60 Hz (3600 rpm). The floss collected is chopped in a high shear mixer with 2% lactose (2% w/w of the floss) for 2 minutes at 100 rpm with the choppers turned on.
Two-hundred proof ethanol (0.5% based on weight of the floss) is sprayed on the chopped floss and mixed. The floss is then dried at 45 C for 90 minutes with intermittent mixing. The dried, chopped floss is screened through a 20 mesh screen.
Fast Dissolving Tablet Preparation Fast dissolving tablets are made using the varenicline tartrate microspheres and the floss previously described in this example using the following formulation:
t Tablet Formulation Varenicline taste-masked microspheres 1.13 /a Floss 95.70 %
Grape flavor 0.70 %
Citric acid 1.50 %
Acesulfame potassium 0.20 /a Silicon dioxide 0.25 %
Sodium stearyl fumarate 0.50 %
The coated varenicline microspheres are blended with the sieved floss for 5 minutes in the high shear mixer, followed by the addition of flavors, sweeteners, and citric acid for another three minutes. The silicon dioxide is added and the mix is blended for another two minutes. The final addition of lubricant sodium stearyl fumarate, is blended for an additional two minutes.
The blend is then tabletted on a rotary tablet press using 9 mm flat-faced bevel edge punches to achieve a tablet weight of 255 mg and hardness values between 0.5 lb. to 2.0 lb.
EXAMPLE 4: Porous Matrix Bead A porous matrix bead is made by spray drying an aqueous solution of mannitol:gelatin (95:5). This matrix bead is blended with varenicline tartrate, binder, sweetener, flow agent, colorant, flavors and lubricant to make a tablet with the following composition.
Ingredient Amount in % of Composition grams Varenicline tartrate 1.16 1.16 Spray Dried Matrix Bead 15.3 77.3 Polyethylene Glyco13350 3.2 16.2 Sweeteners 0.6 3.0 Cab-O-Sil (Cabot Corp., Tuscola, IL) 0.14 0.7 Coloring Agents 0.1 0.5 Flavors 0.14 0.7 Magnesium Stearate 0.1 0.5 The mixture is blended for approximately five minutes without the lubricant.
The magnesium stearate is added later and blended for an additional 2 minutes. The blend is compressed using %z inch round punches to produce a tablet weight of approximately 150 mg.
The compressed tablets are sintered at 50 C for 50 minutes in an oven.
EXAMPLE 5: Spray-dried Varenicline tartrate A porous matrix bead is made by spray drying an aqueous solution of varenicline tartrate:mannitol:gelatin (0.4:97:2.6). This matrix bead is blended with other ingredients to make a tablet with the following composition:
Ingredient Amount, g % of Composition Matrix bead with varenicline tartrate 231 77 Polyethylene Glycol, PEG-3350 30 10 Tri-Calcium Phosphate 36 12 Cab-O-Sil (Cabot Corp., Tuscola, IL) 3 1 The mixture is blended for about 3 minutes. The blend is compressed on a rotary tablet press using %2 inch round flat beveled punches to produce a tablet weight of approximately 570 mg. The compressed tablets are sintered at 90 C for 10 minutes in an oven.
EXAMPLE 6: Effervescent Dosage Forms Two fast disintegrating effervescent dosage forms of varenicliine tartrate are shown below. Formulation I has a faster disintegration time than Formulation II.
After blending these formulations, the tablets are compressed using 12 inch shallow concave punches.
Formulation I. (Shorter Disintegration Time) Ingredient Mg per tablet Varenicline tartrate 1.7 Mannitol 119.4 Microcrystalline Cellulose, Silicified 119.4 Sodium carbonate, anhydrous 47 Sodium bicarbonate 105 Citric acid, anhydrous 75 Polyvinylpyrrolidone, cross-linked 25 Colloidal silicon dioxide 2.5 Magnesium stearate 5 Total Tablet weight 500 Formulation II. (Longer Disintegration Time) Ingredient Mg per tablet Varenicline tartrate 1.7 Mannitol 270.8 Sodium carbonate, anhydrous 40 Sodium bicarbonate 105 Citric acid, anhydrous 75 Colloidal silicon dioxide 2.5 Magnesium stearate 5 Total Tablet weight 500 EXAMPLE 7: Effervescent Tablet Coated varenicline tartrate (26.3 wt% potency) 1.0%
Mannitol Powdered 78.7%
Sodium Bicarbonate 2.3%
Citric Acid, Anhydrous 1.7%
Artificial sweetener 4.6%
Crosslinked polyvinyl pyrrolidone 5.8%
Colloidal Silicon dioxide 0.3%
Magnesium Stearate 1.5%
Artificial Flavor 3.8%
Artificial Color 0.3%
Tablet Weight 650.0 mg All of the ingredients shown above are weighed and blended in a V-blender for about 30 minutes. The magnesium stearate is added and the mixture is blended for about an additional 5 minutes. The blend is compressed on a rotary press resulting in 650mg tablets with average hardness values of 35 - 50 Newtons.
EXAMPLE 8: Heat Molded Dosage Form 190 Grams of cocoa butter, 3.4 grams of lecithin and 10 grams of sorbitan monostearate are melted. 20 grams of polyethylene glycol and 2.0 grams polyoxyethylene sorbitan ester is added to the melt. The mixture is mixed for 8 minutes at 120 F, then for another 2 minutes at 110 F. Following the mixing period, 751.8 grams of xylitol powder is added to the mixture along with 0.9 grams of aspartame and 0.6 grams of acesulfame K. The mixture is mixed for 5 minutes at 120 F. 13.6 grams of varenicline tartrate is added and the mixture is mixed for 7 minutes. 0.8 grams of colorant, 2.0 grams of vanilla flavoring and 34.4 grams of peppermint is added to the mixture, resulting in 1029.5 grams of mixture which is mixed for an additional 10 minutes until all the ingredients are thoroughly mixed. The final mixture is molded into the final product resulting in 130mg per molded dosage form.
EXAMPLE 9: Heat Molded Dosage Form A suspension is made by mixing 2 parts of varenicline tartrate, 195.5 parts of mannitol and 0.5 parts of aspartame to 100 parts of 0.4% agar aqueous solution. A 255 mg portion of the suspension is filled into a mold of 10.5 mm in diameter and dried at 30 C under vacuum to remove the water. This results in a fast disintegrating solid dosage form.
EXAMPLE 10: Disintegrant-based Dosage Form Rapidly disintegrating tablets are made from varenicline tartrate multiparticulates using the following formulation.
coated varenicline tartrate (with 10% ethylcellulose) 1.9 mg microcrystalline cellulose 272.1 mg pregelatinized starch (Starch 1500 ; 188.5 mg Colorcon, West Point, PA) aspartame 20.0 mg flavor 15.0 mg magnesium stearate 2.5 mg Total 500 mg The varenicline tartrate drug particles are coated in a fluidized bed by spraying a solution of ethylcellulose in an ethanol/acetone mixture. The other excipients except the magnesium stearate are sieved and mixed with the coated varenicline tartrate particles in a tumbling blender under dry conditions. Lastly the magnesium stearate is added and the mixture is blended an additional 5 minutes.
The mixture is compressed on a rotary tablet press using 16 mm standard round concave (a radius of.,curvature equal to 20 mm) punches and about 165K Newtons of pressure. The tablet hardness is -50 Newtons and the tablets disintegrate rapidly in the mouth.
EXAMPLE 11: Sublimation-based Dosage Form Porous tablets are made by blending the following ingredients and then compressing the mixture into tablets of 0.5 inch diameter and 0.130 inch thickness. The tablets are heated at 72 C under vacuum for 18 hours. This temperature is above the melting point of PEG
3350 and removes the ammonium bicarbonate from the tablet resulting in a porous matrix with a tablet hardness of about 4kp.
INGREDIENTS MG/TABLET
Ammonium bicarbonate (pore former) (300.00) later removed Varenicline tartrate 1.7 Mannitol 166.30 Banana flavor 8.00 Aspartame 4.00 PEG 3350 20.00 PVP-XL 40.00 Sodium stearyl fumarate 10.00 TOTAL 250.00 EXAMPLE 12: Sublimation-based Dosage Form The following ingredients are blended and milled to provide a homogeneous mixture.
The mixture is heated to melt the menthol and dissolve the hydroxypropyl cellulose (Klucel EF, Hercules Inc, Aqualon Div, Wilmington, DE). The molten suspension is heated to 66 C
and stirred for approximately 30 minutes.
Each 1,000 mg suspension contained the following:
Ingredients mg/tablet Menthol (900) later removed Klucel EF 39.2 PEG 3350 39.1 Aspartame 10.0 Orange flavor 10.0 Varenicline 1.7 Total (1,000) molten suspension Total after sublimation 100.0 A die-and-punch assembly is precooled in a dry-ice container (-78 C}. 1,000 mg of molten suspension is charged into the tableting die with the bottom punch in place. Once frozen, the solid tablet (frozen suspension) is removed from the die. The solid tablet is heated at 43 C under vacuum in a sublimator for 18 hours to remove the menthol. The final tablet is about 90% porous. The resultant tablet has good friability properties and rapidly disintegrates.
EXAMPLE 13: Freeze-dried based Dosage Form (a) Preparation of varenicline 0.682 wt% Solution Gelatin (765 g) and mannitol (540 g) are added in a portion of purified water (16 kg) by mixing thoroughly in the bowl of a vacuum mixer. The mix is then heated to 40 C. 2 C.
and homogenized for ten minutes to allow complete dissolution of the solids.
The mix is cooled down to room temperature (20-24 C). When cooled, the varenicline tartrate (10.2 g), the aspartame (90 g), and mint flavor (90 g) are added sequentially to the mix. The mix is then homogenized to ensure complete dissolution of the solids. The remaining water (492 g), is added to the mixer and the bulk mix homogenized to ensure dissolution is complete.
(b) Preparation of varenicline 1mg Units.
250 Milligrams of varenicline 0.682 wt% solution formed in (a) above is dosed into each of one of a series of pre-formed blister pockets having a pocket diameter of about 12 mm. The blister laminate comprises 200 microns PVC (polyvinyl chloride) coated with 40 gsm PVdC (polyvinyl dichloride). The product is frozen immediately in a liquid nitrogen freeze tunnel. The frozen product is then stored below -20 C for a minimum of 12 hours prior to freeze drying in a freeze drier using a drying temperature of +10' C and a chamber pressure of 0.5 mbar. The freeze-dried units are then inspected for the presence of critical defects and the remainder of the batch is sealed with lidding foil consisting of a paper/foil laminate (20,um aluminum).
EXAMPLE 14: Freeze-dried based Dosage Form (a) Preparation of varenicline free base 0.4 wt% Solution Gelatin (792 g) and mannitol (594 g) are added to a portion of purified water (16 kg) by mixing thoroughly in the bowl of a vacuum mixer. The mix is then heated to 40 C. 2 C
and homogenized for ten minutes. The mix is cooled down to room temperature (20-24 C).
When cooled the varenicline free base (72 g) is added. The mix is homogenized to ensure dissolution of the drug. Citric acid (1 66g) is added gradually with stirring, to adjust the solution pH to 3Ø The remaining water (436 g) is added to the mixer and the bulk mix homogenized to ensure dissolution is complete.
(b) Preparation of varenicline 2 mg Units 500 Milligrams of the varenicline 0.4 wt% solution, as formed in (a} above is dosed into each one of a series of pre-formed blister pockets having a pocket diameter of 16 mm.
The blister laminate comprised 200 /um PVC coated with 40 g per square meter PVdC. The product is frozen immediately in a liquid nitrogen freeze tunnel. The frozen product is then stored below -20 C. for a minimum of 12 hours prior to freeze- drying in a freeze drier using a drying temperature of +10 C. and a chamber pressure of 0.5 mbar. The freeze-dried units are then inspected for the presence of critical defects and the remainder of the batch sealed with lidding foil consisting of a paper/foil laminate (20 gm aluminum). Each blister is overwrapped in a preformed sachet by placing the blister in the sachet and sealing the open end of the sachet completely.
Each dosage form or unit has the following composition:
Ingredient Weight(mg) %by weight of composition Purified water USP/EP* 455 91 Varenicline free base 2 0.4 Gelatin EP/USNF 22 4.4 Mannitol EP/USP 16.5 3.3 Citric Acid EP/USP 4.6 0.9 *Signifies removal during the lyophilization process EXAMPLE 15: Sugar-based Dosage Forms A shearform matrix material as defined in US 5,866,163 is prepared in accordance with the formula set forth below: Sugar (Sucrose) 84.75%; Binding Agent (Sorbitol) 15%;
Surfactant (TweenTM 80, Uniqema, New Castle, DE)Ø25%; Total 100%.
The sucrose and sorbitol are mixed until a homogenous blend is produced. To this mixture, the surfactant is added and mixed. The blend is then subjected to flash flow processing in an Econo Floss Machine No. 7025 at approximately 3,600 rpm at a temperature setting of high. The spun material is collected as a floss and is macerated in a mixing machine for about 45 seconds. The resulting material is a reduced volume shearform matrix in uncured condition.
A varenicline tartrate mixture is prepared in accordance with the present invention in accordance with the formula set forth below:
Ingredient By Weight: Shearform Matrix Floss, 92g, varenicline tartrate, 0.57g, High Intensity Artificial Flavor, 6g, Sweetener (Aspartame), 0.8 g, Lecithin (Yelkin DS), 0.35 g, Silica (Syioid 244, Grace Davison, Cambridgeshire, UK), 0.25 g, Orange Color, 0.05 g;
Totals 100 g.
The lecithin and varenicline tartrate are mixed and added to the ground floss material.
The ingredients are mixed in a mechanical mixing apparatus for 15-20 seconds.
The flavors, high intensity sweetener, and Syloid are then added and mechanically mixed with an additional 10-15 seconds. Finally, the color is added and mixed until the blend takes on a homogenous orange color. The mixture has a homogenous density and excellent flow characteristics. The mixture is added in portions of 0.3 grams to a die having a 0.3 inch diameter. The ingredients are then tamped at a pressure of 80 psi. The tamped dosage units are then cured. Some of the tablets are cured for one day at room temperature and then the packages are sealed.
t Tablet Formulation Varenicline taste-masked microspheres 1.13 /a Floss 95.70 %
Grape flavor 0.70 %
Citric acid 1.50 %
Acesulfame potassium 0.20 /a Silicon dioxide 0.25 %
Sodium stearyl fumarate 0.50 %
The coated varenicline microspheres are blended with the sieved floss for 5 minutes in the high shear mixer, followed by the addition of flavors, sweeteners, and citric acid for another three minutes. The silicon dioxide is added and the mix is blended for another two minutes. The final addition of lubricant sodium stearyl fumarate, is blended for an additional two minutes.
The blend is then tabletted on a rotary tablet press using 9 mm flat-faced bevel edge punches to achieve a tablet weight of 255 mg and hardness values between 0.5 lb. to 2.0 lb.
EXAMPLE 4: Porous Matrix Bead A porous matrix bead is made by spray drying an aqueous solution of mannitol:gelatin (95:5). This matrix bead is blended with varenicline tartrate, binder, sweetener, flow agent, colorant, flavors and lubricant to make a tablet with the following composition.
Ingredient Amount in % of Composition grams Varenicline tartrate 1.16 1.16 Spray Dried Matrix Bead 15.3 77.3 Polyethylene Glyco13350 3.2 16.2 Sweeteners 0.6 3.0 Cab-O-Sil (Cabot Corp., Tuscola, IL) 0.14 0.7 Coloring Agents 0.1 0.5 Flavors 0.14 0.7 Magnesium Stearate 0.1 0.5 The mixture is blended for approximately five minutes without the lubricant.
The magnesium stearate is added later and blended for an additional 2 minutes. The blend is compressed using %z inch round punches to produce a tablet weight of approximately 150 mg.
The compressed tablets are sintered at 50 C for 50 minutes in an oven.
EXAMPLE 5: Spray-dried Varenicline tartrate A porous matrix bead is made by spray drying an aqueous solution of varenicline tartrate:mannitol:gelatin (0.4:97:2.6). This matrix bead is blended with other ingredients to make a tablet with the following composition:
Ingredient Amount, g % of Composition Matrix bead with varenicline tartrate 231 77 Polyethylene Glycol, PEG-3350 30 10 Tri-Calcium Phosphate 36 12 Cab-O-Sil (Cabot Corp., Tuscola, IL) 3 1 The mixture is blended for about 3 minutes. The blend is compressed on a rotary tablet press using %2 inch round flat beveled punches to produce a tablet weight of approximately 570 mg. The compressed tablets are sintered at 90 C for 10 minutes in an oven.
EXAMPLE 6: Effervescent Dosage Forms Two fast disintegrating effervescent dosage forms of varenicliine tartrate are shown below. Formulation I has a faster disintegration time than Formulation II.
After blending these formulations, the tablets are compressed using 12 inch shallow concave punches.
Formulation I. (Shorter Disintegration Time) Ingredient Mg per tablet Varenicline tartrate 1.7 Mannitol 119.4 Microcrystalline Cellulose, Silicified 119.4 Sodium carbonate, anhydrous 47 Sodium bicarbonate 105 Citric acid, anhydrous 75 Polyvinylpyrrolidone, cross-linked 25 Colloidal silicon dioxide 2.5 Magnesium stearate 5 Total Tablet weight 500 Formulation II. (Longer Disintegration Time) Ingredient Mg per tablet Varenicline tartrate 1.7 Mannitol 270.8 Sodium carbonate, anhydrous 40 Sodium bicarbonate 105 Citric acid, anhydrous 75 Colloidal silicon dioxide 2.5 Magnesium stearate 5 Total Tablet weight 500 EXAMPLE 7: Effervescent Tablet Coated varenicline tartrate (26.3 wt% potency) 1.0%
Mannitol Powdered 78.7%
Sodium Bicarbonate 2.3%
Citric Acid, Anhydrous 1.7%
Artificial sweetener 4.6%
Crosslinked polyvinyl pyrrolidone 5.8%
Colloidal Silicon dioxide 0.3%
Magnesium Stearate 1.5%
Artificial Flavor 3.8%
Artificial Color 0.3%
Tablet Weight 650.0 mg All of the ingredients shown above are weighed and blended in a V-blender for about 30 minutes. The magnesium stearate is added and the mixture is blended for about an additional 5 minutes. The blend is compressed on a rotary press resulting in 650mg tablets with average hardness values of 35 - 50 Newtons.
EXAMPLE 8: Heat Molded Dosage Form 190 Grams of cocoa butter, 3.4 grams of lecithin and 10 grams of sorbitan monostearate are melted. 20 grams of polyethylene glycol and 2.0 grams polyoxyethylene sorbitan ester is added to the melt. The mixture is mixed for 8 minutes at 120 F, then for another 2 minutes at 110 F. Following the mixing period, 751.8 grams of xylitol powder is added to the mixture along with 0.9 grams of aspartame and 0.6 grams of acesulfame K. The mixture is mixed for 5 minutes at 120 F. 13.6 grams of varenicline tartrate is added and the mixture is mixed for 7 minutes. 0.8 grams of colorant, 2.0 grams of vanilla flavoring and 34.4 grams of peppermint is added to the mixture, resulting in 1029.5 grams of mixture which is mixed for an additional 10 minutes until all the ingredients are thoroughly mixed. The final mixture is molded into the final product resulting in 130mg per molded dosage form.
EXAMPLE 9: Heat Molded Dosage Form A suspension is made by mixing 2 parts of varenicline tartrate, 195.5 parts of mannitol and 0.5 parts of aspartame to 100 parts of 0.4% agar aqueous solution. A 255 mg portion of the suspension is filled into a mold of 10.5 mm in diameter and dried at 30 C under vacuum to remove the water. This results in a fast disintegrating solid dosage form.
EXAMPLE 10: Disintegrant-based Dosage Form Rapidly disintegrating tablets are made from varenicline tartrate multiparticulates using the following formulation.
coated varenicline tartrate (with 10% ethylcellulose) 1.9 mg microcrystalline cellulose 272.1 mg pregelatinized starch (Starch 1500 ; 188.5 mg Colorcon, West Point, PA) aspartame 20.0 mg flavor 15.0 mg magnesium stearate 2.5 mg Total 500 mg The varenicline tartrate drug particles are coated in a fluidized bed by spraying a solution of ethylcellulose in an ethanol/acetone mixture. The other excipients except the magnesium stearate are sieved and mixed with the coated varenicline tartrate particles in a tumbling blender under dry conditions. Lastly the magnesium stearate is added and the mixture is blended an additional 5 minutes.
The mixture is compressed on a rotary tablet press using 16 mm standard round concave (a radius of.,curvature equal to 20 mm) punches and about 165K Newtons of pressure. The tablet hardness is -50 Newtons and the tablets disintegrate rapidly in the mouth.
EXAMPLE 11: Sublimation-based Dosage Form Porous tablets are made by blending the following ingredients and then compressing the mixture into tablets of 0.5 inch diameter and 0.130 inch thickness. The tablets are heated at 72 C under vacuum for 18 hours. This temperature is above the melting point of PEG
3350 and removes the ammonium bicarbonate from the tablet resulting in a porous matrix with a tablet hardness of about 4kp.
INGREDIENTS MG/TABLET
Ammonium bicarbonate (pore former) (300.00) later removed Varenicline tartrate 1.7 Mannitol 166.30 Banana flavor 8.00 Aspartame 4.00 PEG 3350 20.00 PVP-XL 40.00 Sodium stearyl fumarate 10.00 TOTAL 250.00 EXAMPLE 12: Sublimation-based Dosage Form The following ingredients are blended and milled to provide a homogeneous mixture.
The mixture is heated to melt the menthol and dissolve the hydroxypropyl cellulose (Klucel EF, Hercules Inc, Aqualon Div, Wilmington, DE). The molten suspension is heated to 66 C
and stirred for approximately 30 minutes.
Each 1,000 mg suspension contained the following:
Ingredients mg/tablet Menthol (900) later removed Klucel EF 39.2 PEG 3350 39.1 Aspartame 10.0 Orange flavor 10.0 Varenicline 1.7 Total (1,000) molten suspension Total after sublimation 100.0 A die-and-punch assembly is precooled in a dry-ice container (-78 C}. 1,000 mg of molten suspension is charged into the tableting die with the bottom punch in place. Once frozen, the solid tablet (frozen suspension) is removed from the die. The solid tablet is heated at 43 C under vacuum in a sublimator for 18 hours to remove the menthol. The final tablet is about 90% porous. The resultant tablet has good friability properties and rapidly disintegrates.
EXAMPLE 13: Freeze-dried based Dosage Form (a) Preparation of varenicline 0.682 wt% Solution Gelatin (765 g) and mannitol (540 g) are added in a portion of purified water (16 kg) by mixing thoroughly in the bowl of a vacuum mixer. The mix is then heated to 40 C. 2 C.
and homogenized for ten minutes to allow complete dissolution of the solids.
The mix is cooled down to room temperature (20-24 C). When cooled, the varenicline tartrate (10.2 g), the aspartame (90 g), and mint flavor (90 g) are added sequentially to the mix. The mix is then homogenized to ensure complete dissolution of the solids. The remaining water (492 g), is added to the mixer and the bulk mix homogenized to ensure dissolution is complete.
(b) Preparation of varenicline 1mg Units.
250 Milligrams of varenicline 0.682 wt% solution formed in (a) above is dosed into each of one of a series of pre-formed blister pockets having a pocket diameter of about 12 mm. The blister laminate comprises 200 microns PVC (polyvinyl chloride) coated with 40 gsm PVdC (polyvinyl dichloride). The product is frozen immediately in a liquid nitrogen freeze tunnel. The frozen product is then stored below -20 C for a minimum of 12 hours prior to freeze drying in a freeze drier using a drying temperature of +10' C and a chamber pressure of 0.5 mbar. The freeze-dried units are then inspected for the presence of critical defects and the remainder of the batch is sealed with lidding foil consisting of a paper/foil laminate (20,um aluminum).
EXAMPLE 14: Freeze-dried based Dosage Form (a) Preparation of varenicline free base 0.4 wt% Solution Gelatin (792 g) and mannitol (594 g) are added to a portion of purified water (16 kg) by mixing thoroughly in the bowl of a vacuum mixer. The mix is then heated to 40 C. 2 C
and homogenized for ten minutes. The mix is cooled down to room temperature (20-24 C).
When cooled the varenicline free base (72 g) is added. The mix is homogenized to ensure dissolution of the drug. Citric acid (1 66g) is added gradually with stirring, to adjust the solution pH to 3Ø The remaining water (436 g) is added to the mixer and the bulk mix homogenized to ensure dissolution is complete.
(b) Preparation of varenicline 2 mg Units 500 Milligrams of the varenicline 0.4 wt% solution, as formed in (a} above is dosed into each one of a series of pre-formed blister pockets having a pocket diameter of 16 mm.
The blister laminate comprised 200 /um PVC coated with 40 g per square meter PVdC. The product is frozen immediately in a liquid nitrogen freeze tunnel. The frozen product is then stored below -20 C. for a minimum of 12 hours prior to freeze- drying in a freeze drier using a drying temperature of +10 C. and a chamber pressure of 0.5 mbar. The freeze-dried units are then inspected for the presence of critical defects and the remainder of the batch sealed with lidding foil consisting of a paper/foil laminate (20 gm aluminum). Each blister is overwrapped in a preformed sachet by placing the blister in the sachet and sealing the open end of the sachet completely.
Each dosage form or unit has the following composition:
Ingredient Weight(mg) %by weight of composition Purified water USP/EP* 455 91 Varenicline free base 2 0.4 Gelatin EP/USNF 22 4.4 Mannitol EP/USP 16.5 3.3 Citric Acid EP/USP 4.6 0.9 *Signifies removal during the lyophilization process EXAMPLE 15: Sugar-based Dosage Forms A shearform matrix material as defined in US 5,866,163 is prepared in accordance with the formula set forth below: Sugar (Sucrose) 84.75%; Binding Agent (Sorbitol) 15%;
Surfactant (TweenTM 80, Uniqema, New Castle, DE)Ø25%; Total 100%.
The sucrose and sorbitol are mixed until a homogenous blend is produced. To this mixture, the surfactant is added and mixed. The blend is then subjected to flash flow processing in an Econo Floss Machine No. 7025 at approximately 3,600 rpm at a temperature setting of high. The spun material is collected as a floss and is macerated in a mixing machine for about 45 seconds. The resulting material is a reduced volume shearform matrix in uncured condition.
A varenicline tartrate mixture is prepared in accordance with the present invention in accordance with the formula set forth below:
Ingredient By Weight: Shearform Matrix Floss, 92g, varenicline tartrate, 0.57g, High Intensity Artificial Flavor, 6g, Sweetener (Aspartame), 0.8 g, Lecithin (Yelkin DS), 0.35 g, Silica (Syioid 244, Grace Davison, Cambridgeshire, UK), 0.25 g, Orange Color, 0.05 g;
Totals 100 g.
The lecithin and varenicline tartrate are mixed and added to the ground floss material.
The ingredients are mixed in a mechanical mixing apparatus for 15-20 seconds.
The flavors, high intensity sweetener, and Syloid are then added and mechanically mixed with an additional 10-15 seconds. Finally, the color is added and mixed until the blend takes on a homogenous orange color. The mixture has a homogenous density and excellent flow characteristics. The mixture is added in portions of 0.3 grams to a die having a 0.3 inch diameter. The ingredients are then tamped at a pressure of 80 psi. The tamped dosage units are then cured. Some of the tablets are cured for one day at room temperature and then the packages are sealed.
EXAMPLE 16: Consumable Film Dosage Form 165.4 Grams of Kollidon 30 (BASF Corporation, Florham Park, NJ) are dissolved in a solution of 720 ml water and 2660 ml ethanol at ambient temperature with stirring. 220.5 g hydroxypropyl methylcellulose is then added at 55-60 C. and stirred vigorously until clear and homogeneous. The mixture is then allowed to cool. While stirring 78.75 g flavor is added followed by a mixture of 28.88 g varenicline free base and 31.5 g caramel liquid dissolved- in 120 ml water. The clear, tan-colored solution is allowed to cool to room temperature and coated onto a suitable carrier material, for example non-siliconized, polyethylene-coated kraft paper using conventional coating/drying equipment. Coating gap and web speed are adjusted to achieve a dry film thickness between 20 and 50 micrometer. The drying temperature depends on the length of the drying oven and the web speed and is adjusted to remove the solvents completely, or almost completely, from the film. The dry film is cut into pieces of a shape and size suitable for the intended use so as to deliver a varenicline dose between 1-2 mg per piece.
EXAMPLE 17: Consumable Film Dosage Form Pullulan film composition of varenicline tartrate is prepared using the following steps:
A. dissolve aspartame (1.9 mg), acesulfame potassium salt (0.68mg) and varenicline tartrate (4 mg) in purified water to form an aqueous mixture;
B. mix pullulan (21.8 mg), xanthan gum (0.08 mg), locust bean gum (0.95 mg) and carrageenan (0.41 mg) together in powder form to form a powder mixture;
C. add the powder mixture from step B to the aqueous mixture from step A to form a hydrated polymer gel;
D. stir the hydrated polymer from step C at slow speed (about 50-100 RPM) overnight at room temperature;
E. mix and dissolve monomenthyl succinate (0.14 mg), olive oil (0.68 mg), and menthol (2.7 mg) and propylene glycol (4.1 mg);
F. add titanium dioxide (0.34 mg), Polysorbate 80 (0.47 mg) and Atmos 300 (0.47 mg) to the oil mixture from step E;
G. add the oil mixture from step F to the hydrated polymer gel from step D and mix until uniform;
H. cast the uniform mixture from step G on a suitable backing; and, 1. dry the cast mixture to form a film.
Approximate dose weight assuming complete evaporation of water from the film after drying is 38 mg.
EXAMPLE 18: Consumable Film Dosage Form 15 Grams of sorbitol, 6 g of glycerol, 0.5 g of polysorbate 80 (TweenTM 80, Uniqema, New Castle, DE), 2 g of BrijTM 35 (Uniqema, New Castle, DE), 25 g of lemon mint flavor, 3 g of aspartame, 15 g of 1-menthol, 8 g of varenicline tartrate and 3 g. of citric acid are stirred at 60 C. in a mixture of 250 g water and 250 g ethanol until a clear solution has been formed. To the solution, 30 g of hydroxypropyl methylcellulose are added slowly under stirring until a clear and homogeneous solution has been formed. The resulting= solution is allowed to cool to room temperature and coated onto a suitable carrier material, for example non-siliconized, polyethylene-coated kraft paper using conventional coating/drying equipment.
Coating gap and web speed are adjusted to achieve a dry film thickness between 20 and 50 gm. The drying temperature depends on the length of the drying oven and the web speed and is adjusted to remove the solvents completely, or almost completely, from the film. The resulting film is peeled off the carrier web and cut into pieces of a shape and size suitable for a 1 -2 mg dose of varenicline free base (approximately equivalent to 1.7- 3.4 mg varenicline tartrate).
EXAMPLE 19: Consumable Film Dosage Form Varenicline tartrate (1.45 gm) was dissolved in purified water (120 gm).
Following this, potassium sorbate (0.098 gm) was added and dissolved in the aqueous solution. In a separate container xanthan gum (0.098 gm), locust bean gum (0.114 gm), carrageenan (0.49 gm) and pullulan (26.12 gm) were mixed. The mixture of gums was slowly added to the aqueous solution of varenicline tartrate with rapid mixing. The resulting mixture was allowed to stir 2 - 4 hours to allow the gums to hydrate. After this, glycerin (1.63 gm) was added and the resulting solution was thoroughly stirred. A thin film was then cast as in the example above and after drying 80 strips were cut (each approximately 1.33 x 1.33 inch square).
Varenicline tartrate comprised 1.7 mg/dose or 0.98 mg mgA in each 1.33 inch square film strip.
EXAMPLE 20: PharmaburstTM tablet Varenicline tartrate was tableted as described below using PharmaburstT"' from SPI
Pharma. Varenicline tartrate (0.171 gm - 1.71% of total formulation) was added to PharmaburstT"' B2 (9.68gm - 96.8% total formulation) (SPI Pharma, New Castle, DE) in an amber glass bottle. The two components were blended using a Turbula Shaker Mixer (Glen Mills Inc, Clifton, NJ) for 20 minutes. Magnesium stearate (0.15 gm - 1.5% of total formulation) was then added to the blend. This mixture was then blended using a Turbula Shaker Mixer for an additional 3 minutes. The lubed mixture was tableted as 100mg/tablet on the Manesty F-Press (Thomas Engineering Inc., Hoffman Estates, IL) using '/a"
flat face beveled tooling. The resultant 1 mgA varenicline tablets had a tablet hardness of about 6 kP
(range 4-8 kP).
EXAMPLE 17: Consumable Film Dosage Form Pullulan film composition of varenicline tartrate is prepared using the following steps:
A. dissolve aspartame (1.9 mg), acesulfame potassium salt (0.68mg) and varenicline tartrate (4 mg) in purified water to form an aqueous mixture;
B. mix pullulan (21.8 mg), xanthan gum (0.08 mg), locust bean gum (0.95 mg) and carrageenan (0.41 mg) together in powder form to form a powder mixture;
C. add the powder mixture from step B to the aqueous mixture from step A to form a hydrated polymer gel;
D. stir the hydrated polymer from step C at slow speed (about 50-100 RPM) overnight at room temperature;
E. mix and dissolve monomenthyl succinate (0.14 mg), olive oil (0.68 mg), and menthol (2.7 mg) and propylene glycol (4.1 mg);
F. add titanium dioxide (0.34 mg), Polysorbate 80 (0.47 mg) and Atmos 300 (0.47 mg) to the oil mixture from step E;
G. add the oil mixture from step F to the hydrated polymer gel from step D and mix until uniform;
H. cast the uniform mixture from step G on a suitable backing; and, 1. dry the cast mixture to form a film.
Approximate dose weight assuming complete evaporation of water from the film after drying is 38 mg.
EXAMPLE 18: Consumable Film Dosage Form 15 Grams of sorbitol, 6 g of glycerol, 0.5 g of polysorbate 80 (TweenTM 80, Uniqema, New Castle, DE), 2 g of BrijTM 35 (Uniqema, New Castle, DE), 25 g of lemon mint flavor, 3 g of aspartame, 15 g of 1-menthol, 8 g of varenicline tartrate and 3 g. of citric acid are stirred at 60 C. in a mixture of 250 g water and 250 g ethanol until a clear solution has been formed. To the solution, 30 g of hydroxypropyl methylcellulose are added slowly under stirring until a clear and homogeneous solution has been formed. The resulting= solution is allowed to cool to room temperature and coated onto a suitable carrier material, for example non-siliconized, polyethylene-coated kraft paper using conventional coating/drying equipment.
Coating gap and web speed are adjusted to achieve a dry film thickness between 20 and 50 gm. The drying temperature depends on the length of the drying oven and the web speed and is adjusted to remove the solvents completely, or almost completely, from the film. The resulting film is peeled off the carrier web and cut into pieces of a shape and size suitable for a 1 -2 mg dose of varenicline free base (approximately equivalent to 1.7- 3.4 mg varenicline tartrate).
EXAMPLE 19: Consumable Film Dosage Form Varenicline tartrate (1.45 gm) was dissolved in purified water (120 gm).
Following this, potassium sorbate (0.098 gm) was added and dissolved in the aqueous solution. In a separate container xanthan gum (0.098 gm), locust bean gum (0.114 gm), carrageenan (0.49 gm) and pullulan (26.12 gm) were mixed. The mixture of gums was slowly added to the aqueous solution of varenicline tartrate with rapid mixing. The resulting mixture was allowed to stir 2 - 4 hours to allow the gums to hydrate. After this, glycerin (1.63 gm) was added and the resulting solution was thoroughly stirred. A thin film was then cast as in the example above and after drying 80 strips were cut (each approximately 1.33 x 1.33 inch square).
Varenicline tartrate comprised 1.7 mg/dose or 0.98 mg mgA in each 1.33 inch square film strip.
EXAMPLE 20: PharmaburstTM tablet Varenicline tartrate was tableted as described below using PharmaburstT"' from SPI
Pharma. Varenicline tartrate (0.171 gm - 1.71% of total formulation) was added to PharmaburstT"' B2 (9.68gm - 96.8% total formulation) (SPI Pharma, New Castle, DE) in an amber glass bottle. The two components were blended using a Turbula Shaker Mixer (Glen Mills Inc, Clifton, NJ) for 20 minutes. Magnesium stearate (0.15 gm - 1.5% of total formulation) was then added to the blend. This mixture was then blended using a Turbula Shaker Mixer for an additional 3 minutes. The lubed mixture was tableted as 100mg/tablet on the Manesty F-Press (Thomas Engineering Inc., Hoffman Estates, IL) using '/a"
flat face beveled tooling. The resultant 1 mgA varenicline tablets had a tablet hardness of about 6 kP
(range 4-8 kP).
EXAMPLE 21 - PharmaburstT'" tablet Fast disintegrating tablets are made with coated varenicline tartrate and PharmaburstT"' B2 using the following formulation (given in mg/tablet):
coated varerticline tartrate (with 10% ethylcellulose) 1.9 mg PharmaburStTm B2 96.6 mg magnesium stearate 1.5 mg Coated varenicline tartrate is added to PharmaburStTm B2 (SPI Pharma, New Castle, DE) in an amber glass bottle. The two components are blended using a Turbula Shaker Mixer (Glen Mills Inc, Clifton, NJ) for 20 minutes. Magnesium stearate (0.15 gm - 1.5% of total formulation) is added to the blend. This mixture is then blended using a Turbula Shaker Mixer for an additional 3 minutes. The lubed mixture is tableted as 100mg/tablet on the Manesty F-Press using'/4" flat face beveled tooling to a tablet hardness of about 6 kP.
EXAMPLE 22 - PharmaburstTM tablet Fast disintegrating tablets are made using varenicline tartrate and PharmaburStTm B2 using the following formulation (given in mg/tablet):
varenicline tartrate 1.7mg PharmaburstT"" B2 94 mg flavor 2 mg artificial sweetener 0.25 mg sodium stearyl fumerate 2 mg Varenicline tartrate, PharmaburStTm B2, flavor and artificial sweetener are blended for 20 minutes in a glass bottle using a Turbula0 Shaker Mixer (Glen Mills Inc, Clifton, NJ).
The lubricant sodium stearyl fumerate is added and the mixture is blended an additional 3 minutes in a Turbula Shaker Mixer mixer. The lubed mixture is tableted as 100mg/tablet on a Manesty F-Press using '/4" flat face beveled tooling to obtain a tablet hardness of about 6 kP.
EXAMPLE 23 - PharmaburstTM tablet made with varenicline multiparticulates Fast disintegrating tablets are made using microparticulates of varenicline.
The multiparticulates are made by a melt spray congeal process using the following formulation.
Varenicline is incorporated into multiparticulates to provide taste masking of the drug using the following procedure. The multiparticulates consist of 35 wt%
Varenicline in a carrier of 55 wt% glyceryl mono-, di- and tribehenates (Compritol 888 ATO from Gattefosse Corporation of Paramus, New Jersey) and 10 wt% of poloxamer 407 (commercially available as Pluronic F127 or Lutrol F127 from BASF Corporation ofFlorham Park, New Jersey). To form the multiparticulates about 2200 g of the Compritol and about 400 g of the Pluronic are added to a sealed, jacketed stainless-steel tank (e.g., a Malto-Mat-Universal MMU 5, Krieger AGG, Switzerland) equipped with counter-rotating mixing paddles and a homogenizer. Heating fluid at about 92 C is circulated through the jacket of the tank. After about 60 minutes, the mixture is melted. The mixture is then mixed at about 80 rpm for about 60 minutes. Next, about 1400 g of Varenicline is added to the melt and homogenized for about 5 minutes, resulting in a feed suspension of the Varenicline in the molten components.
Using a gear pump, the feed suspension is pumped at a rate of about 140 g/min to the center of a spinning-disk atomizer. The spinning disk atomizer consists of a bowl-shaped stainless steel disk of 10.1 cm (4 inches) in diameter. The surface of the disk is heated with a thin film heater beneath the disk to about 90 C. The disk is rotated at about 3500 to about 6000 rpm while forming the Varenicline multiparticulates. The particles formed by the spinning-disk atomizer are congealed in ambient air to form the multiparticulates.
The varenicline tartrate multiparticulates are incorportated into the following formulation with PharmaburstT"" B2 (given in mg/tablet):
varenicline multiparticulate 2.85mg PharmaburstT"' B2 93 mg flavor 2 mg artificial sweetener 0.25 mg sodium stearyl fumerate 2 mg Varenicline tartrate multiparticulates, PharmaburstT"' B2, flavor and artificial sweetener are blended for 20 minutes in a glass bottle using a Turbula Shaker Mixer (Glen Mills Inc, Clifton, NJ). The lubricant sodium stearyl fumerate is added and the mixture is blended an additional 3 minutes in a Turbula Shaker Mixer mixer. The lubed mixture is tableted as 100mg/tablet on a Manesty F-Press using'/4' flat face beveled tooling to obtain a tablet hardness of about 6 kP.
EXAMPLE 24: Granulation Preparation A granulation is produced using the following procedure:
Povidone K-30 USP (240.0 gm) is dissolved into distilled water (1,890.0 gm) with agitation.
Mannitol powder USP (11,160 gm) and varenicline tartrate (600.0 gm) are placed in the Zanchetta 50-liter granulator/processor (Romaco USA, Pompton Plains, NJ).
After an initial two-minute dry mix of the powders with the chopper on and the propeller adjusted to 200 rpm, the Povidone K-30 solution is slowly sprayed into the mixing powder bed using an air-driven spray system. The granulation end-point is determined visually by the consistency of the resulting material. The material is then discharged onto trays and dried at 80 C utilizing supplied dry air for a period of six hours to a moisture content of not more than 0.08 %. The dried material is then passed through a hammermill (knives forward) equipped with a U.S.
#40 (420 micron) screen. The milled material is then screened through a U.S.
#200 (75 micron) screen. The material retained on the U.S. #200 (75 micron) screen, about 50 percent, has a mean particle size of 210 microns and is retained for overcoating.
Several batches of the 5.0 % varenicline tartrate granulation produced in accordance with above are overcoated to a 15 % coating level weight based on weight of finished granule using a 5-liter fluidized bed spray coating unit. The coating solution consists of Povidone K-30 USP (360 gm), ethylcellulose NF (495 gm), and distilled acetylated monoglycerides (45 gm).
These, solids are dissolved in a mixture of ethanol (1,350 gm) and acetone NF
(6,750 gm) with agitation. Five kilograms of varenicline tartrate granulation (5.0% w/wp are placed into the 5- liter chamber of the fluidized bed coating unit. The bed is fluidized with air heated to 38 G
and the coating solution is sprayed into the fluidized powder bed using atomized spray at a rate of approximately 50 gm/min until a coating level of 15 % by weight is reached. After the endpoint is reached, the material is allowed to dry in the fluidized bed for an additional ten minutes to drive off any residual solvents. The mean particle size of the overcoated material is about 300 microns.
Throughout this application, various publications, including United States patents, are referenced by author and year and patents by number. Full citations for the publications are listed below. The disclosures of these publications and patents in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
coated varerticline tartrate (with 10% ethylcellulose) 1.9 mg PharmaburStTm B2 96.6 mg magnesium stearate 1.5 mg Coated varenicline tartrate is added to PharmaburStTm B2 (SPI Pharma, New Castle, DE) in an amber glass bottle. The two components are blended using a Turbula Shaker Mixer (Glen Mills Inc, Clifton, NJ) for 20 minutes. Magnesium stearate (0.15 gm - 1.5% of total formulation) is added to the blend. This mixture is then blended using a Turbula Shaker Mixer for an additional 3 minutes. The lubed mixture is tableted as 100mg/tablet on the Manesty F-Press using'/4" flat face beveled tooling to a tablet hardness of about 6 kP.
EXAMPLE 22 - PharmaburstTM tablet Fast disintegrating tablets are made using varenicline tartrate and PharmaburStTm B2 using the following formulation (given in mg/tablet):
varenicline tartrate 1.7mg PharmaburstT"" B2 94 mg flavor 2 mg artificial sweetener 0.25 mg sodium stearyl fumerate 2 mg Varenicline tartrate, PharmaburStTm B2, flavor and artificial sweetener are blended for 20 minutes in a glass bottle using a Turbula0 Shaker Mixer (Glen Mills Inc, Clifton, NJ).
The lubricant sodium stearyl fumerate is added and the mixture is blended an additional 3 minutes in a Turbula Shaker Mixer mixer. The lubed mixture is tableted as 100mg/tablet on a Manesty F-Press using '/4" flat face beveled tooling to obtain a tablet hardness of about 6 kP.
EXAMPLE 23 - PharmaburstTM tablet made with varenicline multiparticulates Fast disintegrating tablets are made using microparticulates of varenicline.
The multiparticulates are made by a melt spray congeal process using the following formulation.
Varenicline is incorporated into multiparticulates to provide taste masking of the drug using the following procedure. The multiparticulates consist of 35 wt%
Varenicline in a carrier of 55 wt% glyceryl mono-, di- and tribehenates (Compritol 888 ATO from Gattefosse Corporation of Paramus, New Jersey) and 10 wt% of poloxamer 407 (commercially available as Pluronic F127 or Lutrol F127 from BASF Corporation ofFlorham Park, New Jersey). To form the multiparticulates about 2200 g of the Compritol and about 400 g of the Pluronic are added to a sealed, jacketed stainless-steel tank (e.g., a Malto-Mat-Universal MMU 5, Krieger AGG, Switzerland) equipped with counter-rotating mixing paddles and a homogenizer. Heating fluid at about 92 C is circulated through the jacket of the tank. After about 60 minutes, the mixture is melted. The mixture is then mixed at about 80 rpm for about 60 minutes. Next, about 1400 g of Varenicline is added to the melt and homogenized for about 5 minutes, resulting in a feed suspension of the Varenicline in the molten components.
Using a gear pump, the feed suspension is pumped at a rate of about 140 g/min to the center of a spinning-disk atomizer. The spinning disk atomizer consists of a bowl-shaped stainless steel disk of 10.1 cm (4 inches) in diameter. The surface of the disk is heated with a thin film heater beneath the disk to about 90 C. The disk is rotated at about 3500 to about 6000 rpm while forming the Varenicline multiparticulates. The particles formed by the spinning-disk atomizer are congealed in ambient air to form the multiparticulates.
The varenicline tartrate multiparticulates are incorportated into the following formulation with PharmaburstT"" B2 (given in mg/tablet):
varenicline multiparticulate 2.85mg PharmaburstT"' B2 93 mg flavor 2 mg artificial sweetener 0.25 mg sodium stearyl fumerate 2 mg Varenicline tartrate multiparticulates, PharmaburstT"' B2, flavor and artificial sweetener are blended for 20 minutes in a glass bottle using a Turbula Shaker Mixer (Glen Mills Inc, Clifton, NJ). The lubricant sodium stearyl fumerate is added and the mixture is blended an additional 3 minutes in a Turbula Shaker Mixer mixer. The lubed mixture is tableted as 100mg/tablet on a Manesty F-Press using'/4' flat face beveled tooling to obtain a tablet hardness of about 6 kP.
EXAMPLE 24: Granulation Preparation A granulation is produced using the following procedure:
Povidone K-30 USP (240.0 gm) is dissolved into distilled water (1,890.0 gm) with agitation.
Mannitol powder USP (11,160 gm) and varenicline tartrate (600.0 gm) are placed in the Zanchetta 50-liter granulator/processor (Romaco USA, Pompton Plains, NJ).
After an initial two-minute dry mix of the powders with the chopper on and the propeller adjusted to 200 rpm, the Povidone K-30 solution is slowly sprayed into the mixing powder bed using an air-driven spray system. The granulation end-point is determined visually by the consistency of the resulting material. The material is then discharged onto trays and dried at 80 C utilizing supplied dry air for a period of six hours to a moisture content of not more than 0.08 %. The dried material is then passed through a hammermill (knives forward) equipped with a U.S.
#40 (420 micron) screen. The milled material is then screened through a U.S.
#200 (75 micron) screen. The material retained on the U.S. #200 (75 micron) screen, about 50 percent, has a mean particle size of 210 microns and is retained for overcoating.
Several batches of the 5.0 % varenicline tartrate granulation produced in accordance with above are overcoated to a 15 % coating level weight based on weight of finished granule using a 5-liter fluidized bed spray coating unit. The coating solution consists of Povidone K-30 USP (360 gm), ethylcellulose NF (495 gm), and distilled acetylated monoglycerides (45 gm).
These, solids are dissolved in a mixture of ethanol (1,350 gm) and acetone NF
(6,750 gm) with agitation. Five kilograms of varenicline tartrate granulation (5.0% w/wp are placed into the 5- liter chamber of the fluidized bed coating unit. The bed is fluidized with air heated to 38 G
and the coating solution is sprayed into the fluidized powder bed using atomized spray at a rate of approximately 50 gm/min until a coating level of 15 % by weight is reached. After the endpoint is reached, the material is allowed to dry in the fluidized bed for an additional ten minutes to drive off any residual solvents. The mean particle size of the overcoated material is about 300 microns.
Throughout this application, various publications, including United States patents, are referenced by author and year and patents by number. Full citations for the publications are listed below. The disclosures of these publications and patents in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
Claims (14)
1. A fast disintegrating dosage form of varenicline, comprising:
an effective amount of varenicline or a pharmaceutically acceptable salt thereof; and, at least one pharmaceutically acceptable excipient.
an effective amount of varenicline or a pharmaceutically acceptable salt thereof; and, at least one pharmaceutically acceptable excipient.
2. The fast disintegrating dosage form of varenicline according to claim 1, wherein said dosage form comprises a pharmaceutically acceptable salt of 5,8,14-triazatetra-cyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2(11),3,5,7,9-pentaene.
3. The fast disintegrating dosage form of varenicline according to claim 1, wherein said dosage form disintegrates in a patient's oral cavity in less than three minutes.
4. The fast disintegrating dosage form of varenicline according to claim 3 wherein said dosage form disintegrates in a patient's oral cavity within from about two seconds to two minutes.
5. The fast disintegrating dosage form of varenicline according to claim 3 wherein said dosage form disintegrates in a patient's oral cavity within from about two seconds to about one minute.
6. The fast disintegrating dosage form of varenicline according to claim 1, wherein at least one pharmaceutically acceptable excipient is selected from the group consisting of at least one binder, a salivating agent, a diluent, a sweetener, a disintegrant, flavoring and a film coating agent.
7. The fast disintegrating dosage form of varenicline according to claim 6, wherein said excipient is from about 70 wt% to about 95 wt% and is selected from the group consisting of mannitol, xylitol, sorbitol, sucrose, trehalose, aspartame, monomenthyl succinate, glycerol, menthol, xanthan gum, locust bean gum, carrageenan, lecithin, microcrystalline cellulose, powdered cellulose, starch, pregelatinized starch, fast dissolving carbohydrates, silica, colloidal silica, potassium sorbate, acesulfame potassium salt, sodium bicarbonate, calcium carbonate, calcium phosphate dibasic, tribasic calcium phosphate, calcium sulfate, magnesium carbonate, magnesium oxide, poloxamers, hydroxypropyl methylcellulose, citric acid, povidove, pullulan, Brij.TM.35, gelatin, polyethylene glycol, , glyceryl mono, di- and tribehenates, sorbitan monostearate, polysorbate 80, cocoa butter, carnauba wax and combinations thereof.
8. The fast disintegrating dosage form of varenicline according to claim 6 wherein said excipient is from about 70 wt% to about 95 wt% and is selected from the group consisting of mannitol, sorbitol, xylitol, microcrystalline cellulose, silicified microcrystalline cellulose, cellulosic polymers, hydroxypropyl methylcellulose (HPMC) and hydroxypropyl cellulose (HPC), pullulan and fast dissolving carbohydrates.
9. The fast disintegrating dosage form of varenicline according to claim 1, further comprising a film coating.
10. The fast disintegrating dosage form of varenicline according to claim 1, wherein said pharmaceutically acceptable salt is selected from the group consisting of L-tartrate salt and a citrate salt.
11. The fast disintegrating dosage form of varenicline according to claim 1, further comprising an immediate release dosage form suitable for administration to a subject, which dosage form, when dosed to said subject, results in a maximum plasma concentration (C max) of said varenicline in an initial administration to said subject, which is, on average, greater than 80% of the corresponding C max determined for an equal dose of said varenicline in the form of an immediate release bolus.
12. A method of treating a disorder or condition selected from the group consisting of inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions; dependencies on, or addictions to, nicotine, tobacco products, alcohol, benzodiazepines, barbiturates, opioids or cocaine; headache, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's Chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age related cognitive decline, epilepsy, petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD), and Tourette's Syndrome, in a subject suffering therefrom, comprising administering to the subject an effective amount of the fast disintegrating dosage form of varenicline of claim 1.
13. A method for reducing nicotine addiction, aiding in the cessation of, or lessening of tobacco use in a subject comprising administering to the subject an effective amount of the fast disintegrating dosage form of varenicline of claim 1.
14. The method according to claim 13, wherein said administering step is further defined as administering the pharmaceutically acceptable salt selected from the group consisting of the L- tartrate and the citrate salt.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64208305P | 2005-01-07 | 2005-01-07 | |
US60/642,083 | 2005-01-07 | ||
PCT/IB2005/003979 WO2006072832A1 (en) | 2005-01-07 | 2005-12-22 | Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2593432A1 true CA2593432A1 (en) | 2006-07-13 |
Family
ID=36129747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002593432A Abandoned CA2593432A1 (en) | 2005-01-07 | 2005-12-22 | Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1843769A1 (en) |
JP (1) | JP2008526827A (en) |
CA (1) | CA2593432A1 (en) |
WO (1) | WO2006072832A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110086086A1 (en) * | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
JP5228359B2 (en) * | 2007-04-12 | 2013-07-03 | ニプロ株式会社 | Active ingredient particles, process for producing the same and orally disintegrating tablets |
CA2686035C (en) * | 2007-05-08 | 2016-01-05 | Hercules Incorporated | Robust rapid disintegration tablet formulation |
WO2009111623A2 (en) * | 2008-03-06 | 2009-09-11 | Dr. Reddy's Laboratories Ltd. | Amorphous varenicline tartrate |
JP2012509321A (en) * | 2008-11-21 | 2012-04-19 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | 4- [6-Methoxy-7- (3-piperidin-1-yl-propoxy) quinazolin-4-yl] piperazine-1-carboxylic acid (4-isopropoxy) for the treatment of cancer and other diseases or disorders Phenyl) -amide lactate and pharmaceutical composition thereof |
CN103919742B (en) * | 2008-11-25 | 2017-04-12 | 田边三菱制药株式会社 | Orally Rapidly Disintegrating Tablet And Process For Producing Same |
JP5637624B2 (en) * | 2009-02-12 | 2014-12-10 | 富士化学工業株式会社 | Disintegrating particle composition and fast disintegrating compression molding using the same |
JP2010285415A (en) * | 2009-06-15 | 2010-12-24 | Hisamitsu Pharmaceut Co Inc | Package of transdermal drug delivery system containing varenicline or pharmaceutically acceptable varenicline acid addition salt |
KR101828630B1 (en) * | 2010-07-09 | 2018-02-12 | 데이진 화-마 가부시키가이샤 | Orally disintegrating tablet |
JP6045237B2 (en) * | 2012-07-27 | 2016-12-14 | 旭化成株式会社 | Tablet-type thickener |
JP6045238B2 (en) * | 2012-07-27 | 2016-12-14 | 旭化成株式会社 | Tablet containing thickening polysaccharide |
US10413516B2 (en) * | 2013-05-09 | 2019-09-17 | Cure Pharmaceutical Corporation | Thin film with high load of active ingredient |
CN104548113B (en) * | 2014-12-11 | 2017-12-01 | 天津博科林药品包装技术有限公司 | A kind of production technology of film coating agent |
CN105434383B (en) * | 2015-12-31 | 2021-08-03 | 山东新时代药业有限公司 | Levamlodipine besylate tablet and preparation method thereof |
CN106943367B (en) * | 2016-01-06 | 2020-07-14 | 山东新时代药业有限公司 | Afatinib maleate tablet and preparation method thereof |
IT201600078683A1 (en) * | 2016-07-27 | 2018-01-27 | Mattia Saporiti | EDIBLE MATRIX FOR VETERINARY AND ZOOTECHNICAL USE AND RELATED PRODUCTION METHOD |
US11266658B2 (en) * | 2017-03-03 | 2022-03-08 | Ctc Bio, Inc. | Preparation, comprising inclusion complex of varenicline or pharmaceutically acceptable salt thereof, for oral administration |
WO2018154395A2 (en) | 2018-06-11 | 2018-08-30 | Alvogen Malta Operations (Row) Ltd | Controlled release pharmaceutical composition of varenicline |
CN109432022B (en) * | 2018-12-10 | 2021-07-06 | 江苏豪森药业集团有限公司 | Pharmaceutical composition containing valnemadex tartrate and preparation method thereof |
WO2022230925A1 (en) * | 2021-04-28 | 2022-11-03 | アスパック企業株式会社 | Pyoderma ameliorating agent |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1448235T1 (en) * | 2001-11-30 | 2007-08-31 | Pfizer Prod Inc | ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF 5,8,14-TRIAZATETRACYCLO 10.3.1.0(2,11).0(4,9)?å-HEXADECA-2(11)3,5,7,9-PENTAENE |
-
2005
- 2005-12-22 JP JP2007549963A patent/JP2008526827A/en not_active Abandoned
- 2005-12-22 EP EP05826405A patent/EP1843769A1/en not_active Withdrawn
- 2005-12-22 CA CA002593432A patent/CA2593432A1/en not_active Abandoned
- 2005-12-22 WO PCT/IB2005/003979 patent/WO2006072832A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP1843769A1 (en) | 2007-10-17 |
WO2006072832A1 (en) | 2006-07-13 |
JP2008526827A (en) | 2008-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060057207A1 (en) | Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene | |
CA2593432A1 (en) | Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene | |
US9089490B2 (en) | Orally disintegrating tablets and methods of manufacture | |
AU2002300238C1 (en) | Process for manufacturing bite-dispersion tablets | |
JP4920798B2 (en) | Intraoral quick disintegrating tablet containing two or more kinds of particles | |
KR101011278B1 (en) | Rapidly disintegratable oral tablet | |
JP2007509155A (en) | Drugs containing quetiapine | |
JP4802436B2 (en) | Orally disintegrating composition and orally disintegrating preparation | |
JP2001515028A (en) | A rapidly dissolving oral dosage unit formed under high speed / high pressure conditions | |
JP2002506811A (en) | Polymer-based fast dissolving tablets and process for their production | |
US20040162333A1 (en) | Rapid absorption selective 5-HT agonist formulations | |
JP2010523552A (en) | Method for producing fast-dissolving tablets | |
JP2007517011A (en) | Multiparticulate formulation for oral delivery | |
EP1660050B1 (en) | Ibuprofen-containing fast dissolving tablet | |
JP2002255796A (en) | Rapidly disintegrating tablet in oral cavity and method for producing the same | |
EP1469848B1 (en) | Sedative non-benzodiazepine formulations | |
JP3228335B2 (en) | Orally disintegrating composition and method for producing the same | |
JP6061924B2 (en) | Oral dispersible formulation | |
US20030165566A1 (en) | Sedative non-benzodiazepine formulations | |
KR20050118775A (en) | Orally disintegrating tablet utilizing crystallized solid bridge between sugars and drug particles | |
EP1941878A1 (en) | Sedative non-benzodiazepine formulations | |
AU2003201155B2 (en) | Sedative non-benzodiazepine formulations | |
WO2013098399A1 (en) | Mozavaptan formulations | |
Bhatt et al. | Formulation and Evaluation of Glimepiride Sublingual Tablets | |
JP2002265389A (en) | Tablet and method for producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |